CLINICAL PROTOCOL  
 
 
An Open-Label Phase I/II Pi [INVESTIGATOR_673331]/T olerability and Efficacy of 
Ustekinumab for Symptomatic Gastrointestin al Inflammation Associated with Common 
Variable Immunodeficiency 
 
 
National Institute of Allergy and Infectious Diseases (NIAID) Protocol Number: 
14-I-0153 
 
Sponsored by:   [CONTACT_673368]:   [INVESTIGATOR_673332] J. Fuss, MD 
 
Clinical Development Phase:   I/II 
 
US Food and Drug Administration (FDA) Investigational New Drug (IND) Number: 
121395 
 
IND Sponsor:   Office of Clinical Research Policy  and Regulatory Operations (OCRPRO), 
Division of Clinical Research (DCR), NIAID, NIH 
[ADDRESS_909876] - Room 4B11 
Bethesda, MD [ZIP_CODE] 
Phone: ([PHONE_13962] 
Fax: ([PHONE_13963]  
 
Sponsor Medical Monitor:   Marc Teitelbaum, MD, MS 
Leidos Biomedical Research, Inc. 
[ADDRESS_909877], Room 253 
Frederick, MD  [ZIP_CODE] 
Phone: ([PHONE_13964] 
Fax: ([PHONE_13965] 
 
NIAID Institutional Review Board (IRB): 
[ADDRESS_909878], Room 4B31 
Bethesda, MD [ZIP_CODE] 
Phone ([PHONE_13966] 
 
Version Number:  13 
 
Version Date:  April 17, 2018 
 
 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 2 
STUDY STAFF ROSTER 
Principal Investigator: [INVESTIGATOR_673333], MD 
National Institutes of Health (NIH) National Institutes of Allergy and Infectious Diseases (NIAID) Laboratory of Clinical Immunology and Microbiology (LCIM) [ADDRESS_909879]., CRC 5W-3864 Bethesda, MD [ZIP_CODE] Phone: [PHONE_13967] Fax: [PHONE_13968]  Email: [EMAIL_12873]  
     
Associate Investigators:      
Warren Strober, MD          NIAID/LCIM   [PHONE_13969] 
Michael Yao, MD NIAID Special Volunteer  [PHONE_13970] Patricia Littel, RN, BSN  NIAID/LCIM   [PHONE_768] Sandra Maxwell, RN, BSN  NIAID/LCIM   [PHONE_13971] Kim Montgomery-Recht, RN, BSN  Leidos Biomedical Research, [PHONE_13972]    Inc., Contractor     
Collaborators: 
Andriy Morgun, PhD 
Assistant Professor, Dept. of Pharmaceutical Sciences 
College of Pharmacy, Oregon State University [ADDRESS_909880] Corvallis, OR [ZIP_CODE] Phone: [PHONE_13973] Email: [EMAIL_12874]  
Collaboration role:  Gene expression/microbiota an alysis of deidentified human lamina propria 
biopsy tissue of patients with CVID enteropathy  Natalia Shulzhenko, MD, PhD Assistant [CONTACT_289309] of Veterinary Medicine, Oregon State University 
105 Dryden Hall 
Corvallis, OR [ZIP_CODE] Phone:  [PHONE_13974] Email:  [EMAIL_12875]  
Collaboration role:  Gene expression/microbiota an alysis of deidentified human lamina propria 
biopsy tissue of patients with CVID enteropathy  Ronald Hornung, PhD 
Leidos Biomedical Research, Inc. 
[ADDRESS_909881] 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 3 
Frederick, MD [ZIP_CODE] 
Phone: [PHONE_13975] 
E-mail: [EMAIL_12876]  
Collaboration role:  Gene expression and cytokine  analysis of deidentified human lamina propria 
biopsy tissue and blood of patients with CVID enteropathy  Jing Qin, PhD National Institutes of Health (NIH) National Institutes of Allergy and Infectious Diseases (NIAID) Biostatistics Research Branch [ADDRESS_909882], MSC 7609 Bethesda, MD [ZIP_CODE] Phone: [PHONE_13976] 
Email : [EMAIL_12877] 
Collaboration role:  Statistician  
 
Eric Delwart, PhD 
Blood Systems Research Institute (BSRI) [ADDRESS_909883]. San Francisco, CA [ZIP_CODE] Phone:  [PHONE_13977] Email:  [EMAIL_12878]  
Collaboration role: Virome analysis of deidentified human lamina propria biopsy tissue of patients with CVID enteropathy   
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909884] OF FIGURES ............................................................................................................... ......... 7  
TABLE OF ABBREVIATIONS .................................................................................................... 8  
PROTOCOL SUMMARY ............................................................................................................ 1 0 
PRÉCIS ........................................................................................................................ ................. 12  
1.0 INTRODUCTION ............................................................................................................ 13  
1.1 COMMON VARIABLE IMMUNODEFICIENCY (CVID) ....................................................... 13  
1.1.1  Current Therapy for CVID........................................................................................ 14  
1.1.2  Gastrointestinal Manifestations of CVID ................................................................. 15  
1.1.3  Current Immunology Research in CVID Patients .................................................... 16  
1.1.4  Preliminary Data in CVID Enteropathy .................................................................... 18  
1.2 STUDY AGENT  ............................................................................................................... 19  
1.3 PHARMACOKINETICS  ...................................................................................................... 20  
1.4 CLINICAL EXPERIENCE IN CROHN ’S DISEASE  ................................................................ 20  
1.5 RATIONALE FOR DOSE SELECTION  ................................................................................. 21  
2.0 STUDY OBJECTIVES ..................................................................................................... 22  
2.1 PRIMARY OBJECTIVE  ..................................................................................................... 22  
2.2 SECONDARY OBJECTIVES  ............................................................................................... 22  
3.0 STUDY DESIGN AND METHODS................................................................................ 22  
3.1 STUDY ENDPOINTS  ......................................................................................................... 23  
3.1.1  Primary Endpoint ...................................................................................................... 23  
3.1.2  Secondary Endpoint .................................................................................................. 23  
4.0 INCLUSION AND EXCLUSION CRITERIA ................................................................ 23  
4.1 DIAGNOSIS AND CRITERIA FOR INCLUSION : ................................................................... 24  
4.2 CRITERIA FOR EXCLUSION : ............................................................................................ 24  
4.3 SCREENING AND STUDY PROCEDURES  ........................................................................... 26  
5.0 IMPLEMENTATION ....................................................................................................... 26  
5.1 STUDY POINT 1:  PRE-TREATMENT VISIT - DAY -120  TO -1 ........................................... 26  
5.2 STUDY POINT 2:  TREATMENT #1 VISIT - DAY 0 ............................................................ 27  
5.3 STUDY POINT 3:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #1 ............................. 27  
5.4 STUDY POINT 4:  PHONE CALL - 2 WEEKS AFTER TREATMENT #1 (+/-  3 DAYS ) ............. 28  
5.5 STUDY POINT 5:  TREATMENT #2 VISIT - WEEK 8 (+/-  4 DAYS ) ..................................... 28  
5.6 STUDY POINT 6:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #2 ............................. 28  
5.7 STUDY POINT 7:  PHONE CALL - 2 WEEKS AFTER TREATMENT #2 (+/-  3 DAYS ) .............. 28  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 5 
5.8 STUDY POINT 8:  TREATMENT #3 VISIT - WEEK 16 (+/-  4 DAYS ) ................................... 28  
5.9 STUDY POINT 9:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #3 ............................. 29  
5.10  STUDY POINT 10:  PHONE CALL - 2 WEEKS AFTER TREATMENT #3 (+/-  3 DAYS ) ............ 29  
5.11  STUDY POINT 11:  TREATMENT #4 VISIT - WEEK 24 (+/-  4 DAYS ) ................................. 29  
5.12  STUDY POINT 12:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #4 ........................... 30  
5.13  STUDY POINT 13:  PHONE CALL - 2 WEEKS AFTER TREATMENT #4 (+/-  3 DAYS ) ............ 30  
5.14  STUDY POINT 14:  TREATMENT #5 VISIT - WEEK 32 (+/-  4 DAYS ) ................................. 30  
5.15   STUDY POINT 15:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #5 ........................... 31  
5.16  STUDY POINT 16:  PHONE CALL - 2 WEEKS AFTER TREATMENT #5 (+/-  3 DAYS ) ............ 31  
5.17  STUDY POINT 17:  TREATMENT #6 VISIT - WEEK 40 (+/-  4 DAYS ) ................................. 31  
5.18   STUDY POINT 18:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #6 ........................... 31  
5.19  STUDY POINT 19:  PHONE CALL - 2 WEEKS AFTER TREATMENT #6 (+/-  3 DAYS ) ............ 32  
5.20  STUDY POINT 20:  ENDPOINT VISIT - WEEK 48 (+/-  5 DAYS ) .......................................... [ADDRESS_909885] OF THE STUDY  ............................................................................................... 35  
7.4 RECRUITMENT PLANS AND PROCEDURES  ....................................................................... 35  
7.5 JUSTIFICATION OF THE EXCLUSION OF WOMEN AND CHILDREN (SPECIAL POPULATIONS )
 35  
7.5.1  Exclusion of Children ............................................................................................... 35  
7.5.2  Exclusion of Pregnancy ............................................................................................ 35  
7.5.3  Breastfeeding ............................................................................................................ 35  
8.0 POTENTIAL RISKS AND BENEFITS ........................................................................... 36  
8.1         POTENTIAL BENEFITS  .................................................................................................... 36  
8.2 POTENTIAL HAZARDS AND DISCOMFORTS  ..................................................................... 36  
8.2.1  Risks of Ustekinumab (Stelara®) .............................................................................. 36  
8.2.2  Risks and Discomforts of Phlebotomy ..................................................................... 39  
8.2.3  Risks and Discomforts of EGD and/or Colonoscopy with Biopsies ........................ [ADDRESS_909886] CONFIDENTIALITY  ........................................................................................... 41  
9.0 ASSESSMENT OF SAFETY ........................................................................................... 41  
9.1 DOCUMENTING , RECORDING , AND REPORTING ADVERSE EVENTS  ................................ 41  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 6 
9.2 DEFINITIONS  .................................................................................................................. 42  
9.3 INVESTIGATOR ASSESSMENT OF ADVERSE EVENTS  ...................................................... 44  
9.3.1  Severity ..................................................................................................................... 45 
9.3.2  Causality ................................................................................................................... 4 5 
9.4 INVESTIGATOR REPORTING RESPONSIBILITIES TO THE SPONSOR  .................................. 46  
9.4.1  Adverse Events ......................................................................................................... 46  
9.4.2  Serious Adverse Events ............................................................................................ 46  
9.4.3  Unanticipated Problems ............................................................................................ 46  
9.4.4  Pregnancy .................................................................................................................. 47  
9.5 REPORTING PROCEDURES TO THE NIAID  IRB .............................................................. 47  
9.5.1  Expedited Reporting to the NIAID IRB ................................................................... 47  
9.5.2  Waiver of Reporting Anticipated Protocol Deviations, Expected UPnonAEs and 
Deaths to the NIAID IRB ..................................................................................................... 4 7 
9.5.3  Annual Reporting to the NIAID IRB ........................................................................ 47  
9.6 FOLLOW -UP OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  ............................ 48  
9.7 SPONSOR ’S REPORTING RESPONSIBILITIES  .................................................................... [ADDRESS_909887]  ................................................ 50  
9.11  REPLACEMENT FOR WITHDRAWN SUBJECTS  .................................................................. 50  
9.12  SAFETY OVERSIGHT  ....................................................................................................... 51  
9.12.1  Safety Review and Communications Plan (SRCP) .................................................. 51  
9.12.2  Sponsor Medical Monitor (SMM) ............................................................................ 51  
9.12.3  Safety Monitoring Committee (SMC) ...................................................................... [ADDRESS_909888] KEEPI[INVESTIGATOR_1645]  ...................................................................... 52  
10.1.1  Data Management Responsibilities........................................................................... 52  
10.1.2  Data Capture Methods .............................................................................................. 52  
10.1.3  Types of Data ............................................................................................................ 53  
10.1.4  Source Documents and Access to Source Data/Documents ..................................... [ADDRESS_909889] Retention ...................................................................................................... 53  
10.2  DATA SHARING  .............................................................................................................. 53  
11.0  SPECIMEN COLLECTION AND STORAGE................................................................ 54  
12.0  REMUNERATION........................................................................................................... 54  
REFERENCES .................................................................................................................... ......... 55  
APPENDIX A - PROTOCOL FOR TESTS OF GASTROINTESTINAL FUNCTION ............. 60  
APPENDIX B - STELARA® DATA SHEET ............................................................................. 61  
APPENDIX C - STELARA® PRESCRIBING INFORMATION ............................................... 61  
APPENDIX D - STELARA® PATIENT INFORMATION SHEET .......................................... [ADDRESS_909890] OF TABLES 
Table 1: The probability of at least one subject for various SAE rate with the planned sample size 
(10) .......................................................................................................................... ...................... 33  
Table 2:  The binomial exact 95% for various AE rates with the planned sample size (10) ........ 33  
Table 3:  Summary of Adverse Drug Reactions ........................................................................... [ADDRESS_909891] OF FIGURES 
Figure 1: IL-12 secretion from LPMCs isola ted from endoscopic biopsies of the duodenum and 
colon in CVID patients with or without chronic diarrhea or weight loss. .................................... 16  
Figure 2:  Usktekinumab ....................................................................................................... ........ 17  
 
  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 8 
TABLE OF ABBREVIATIONS 
 
A1AT Alpha-1 Antitrypsin 
AE Adverse event 
AI Associate Investigators  
AR Adverse Reaction  
BTRIS Biomedical Translational Research Information System of the NIH 
CD Crohn's disease  
CD# cluster of differentiation  
CD40L cluster of differentiation [ADDRESS_909892] x-ray  
EGD esophagogastroduodenoscopy  
ELISA enzyme-linked immunosorbent assay 
ESR erythrocyte sedimentation rate 
FDA Federal Drug Administration  
GI gastrointestinal  
GCP Good Clinical Practice  
HBeAg hepatitis B e-antigen  
HBsAg Hepatitis B surface antigen  
Hib Haemophilus influenzae type B (vaccine) 
HIV human immunodeficiency virus  
HRPP Human Research Protection Program 
IATA International Air Transport Association  
ICOS inducible T-cell COStimulator 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
INR International Normalized Ratio 
IRB Institutional Review Board 
IUIS International Union of Immunological Societies 
IVIG intravenous pooled immunoglobulin  
IV intravenous  
LCIM Laboratory of Clinical Immunology and Microbiology 
LPMC lamina propria mononuclear cells  
LPS Lipopolysaccharide 
NIAID National Institutes of Allergy and Infectious Diseases  
NIH National Institutes of Health 
NLH nodular lymphoid hyperplasia  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 9 
OHRP Office for Human Research Protections 
PBMCs peripheral blood mononuclear cells  
OCRPRO Office of Clinical Research Policy and Regulatory Operations 
PCR polymerase chain reaction  
PI [INVESTIGATOR_673334]/ PTT Prothrombin Time, Partial Thromboplastin Time 
SAE Serious adverse event 
SAC Staphylococcus aureus Cowan 
SAR Suspected Adverse Reaction  
SC subcutaneous  
SERF Safety Expedited Report Form  
SMC Safety Monitoring Committee 
SRCP Safety Review and Communication Plan  
S[LOCATION_003]R Serious and Unexpected Su spected Adverse Reaction  
t1⁄2 half-life 
TB tuberculosis  
TGF beta transforming growth factor beta 
Th1 / Th2 T-helper type 1 / type [ADDRESS_909893] upper limit of normal  
UP Unanticipated Problem  
UPnonAE Unanticipated Problem that is not an Adverse Event  
 
  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 10 
PROTOCOL SUMMARY 
Full Title:   An Open-Label Phase I/II Pi[INVESTIGATOR_673331]/Tolerability and Efficacy 
of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated with Common Variable Immunodeficiency  Short Title:   Ustekinumab for CVID-GI 
 Clinical Phase:   I/II 
 IND Sponsor:   NIAID 
 Conducted by:   [CONTACT_18127] / Laboratory of Clinical Immunology and Microbiology (LCIM) 
 
Principal Investigator:   [INVESTIGATOR_673332] J. Fuss, MD 
 Sample Size:  10 subjects  
 
Accrual Ceiling:   10 subjects 
 Study Population:  Subjects with Common Variable Immunodeficiency (CVID) or selective IgG 
subclass deficiency (func tional agammaglobulinemia)  and associated symptomatic 
gastrointestinal inflammation (enteropathy).  Accrual Period:   July 2014 through December 2018 
 
Study Design:  This is an open-label study in CVID or selective IgG subclass deficiency 
(functional agammaglobulinemia) patients wi th active gastrointestinal symptoms (CVID 
enteropathy). Up to 10 eligible adult subjects will  be enrolled at the NIH Clinical Center. This 
study consists of a Pre-Treatment Visit (Day -1 20 to -1), a Day 0 Treatment Visit, a Week 8 
Treatment Visit, a Week 16 Treatment Visit, a Week 24 Treatment Visit, a Week 32 Treatment 
Visit, a Week 40 Treatment Visit and a Week 48 Endpoint Visit.  A treatment dose of ustekinumab 
270 mg (3 doses of 90 mg, either single-use pref illed syringe or single-use vial, depending on 
availability) will be injected subcutaneously in subjects by [CONTACT_673369] 0. 
Subjects will then receive a follow up treatment dose of 90 mg (1 dose of 90 mg) at Week 8, Week 
16, Week 24, Week 32, and Week 40.  Patients will be seen at Week 8, Week 16, Week 24, Week 
32, Week [ADDRESS_909894] already received a single 27 0 mg dose may be eligible for retreatment as 
follows: If they have had a reoccurrence of symptoms, meet study eligibility criteria and are at least 6 months or greater from receiving study agent subjects would receive a treatment dose of 
270 mg (3 doses of 90 mg, either single-use pref illed syringe or single-use vial, depending on 
availability) will be injected subcutaneously in  subjects by [CONTACT_673370] 0 
study point. Subjects will then receive follow up treatment doses of 90 mg (1 dose of 90 mg) at 
the Week 8, Week 16, Week 24, Week 32, and W eek 40 study points. These subjects will be 
classified as Cohort 1. 
 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 11 
Newly enrolled subjects will be assigned into Cohort 2 and will receive ustekinumab doses as 
follows: A treatment dose of 270 mg (3 doses of 90 mg, either single-use prefilled syringe or 
single-use vial, depending on availability) will be injected subcutaneously in subjects by [CONTACT_673371] 0 study point. Subjects w ill then receive follow up treatment doses of 90 
mg (1 dose of 90 mg) at the Week 8, Week 16, Week 24, Week 32, and Week 40 study points.  
 Study Duration:   Individual subject participation will be  48 weeks from administration of study 
agent.  Study Agent:   Stelara
® (ustekinumab), Janssen Biotech, Inc. 
 Primary Objective:   Assess the safety and tolerability of  administration of ustekinumab in CVID 
enteropathy patients by [CONTACT_673372]. 
 
Secondary Objectives:   
x To assess the efficacy of the study agent in alleviating symptoms of CVID enteropathy by 
[CONTACT_673373] 8, Week 16, Week 24, 
Week 32, Week 40 and Week 48 study points with Day 0 baseline values. 
x To assess changes in gut absorption and prot ein loss (D-xylose absorption, 48 hour stool fat 
collection, fecal alpha-1 antitrypsin (A1AT) cl earance) at the Week 24 and Week 48 study 
points by [CONTACT_673374]. 
x To assess changes in mucosal histology score (modified D ’haens scoring) at the Week 48 study 
point by [CONTACT_673375].  
x To measure changes in stimulated cytokine  production and mRNA expression microarray by 
[CONTACT_673376] 48 study point by [CONTACT_673374].  
x To measure changes in gut microbiota and glob al gene expression of inducible interferon and 
metabolic genes at the Week 48 study point  by [CONTACT_673374]. 
x To measure changes in laboratory surrogate efficacy markers of inflammatory bowel disease 
treatments (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], albumin, hemoglobin, platelets) at the Week 8 Week 16, Week 24, Week 32, Week 40 and Week 48 
study points.  
Primary Endpoint:   The primary endpoint of the study is whether treatment with ustekinumab is 
safe and tolerated in the CVID enteropathy patien ts and does not cause a significant increase in 
infection or result in any serious  adverse events (SAEs) that are determined to be definitely, 
probably or possibly related to administration of the study agent.  
Secondary Endpoint:   The secondary endpoint of the study is whether patients respond to the 
treatment with ustekinumab.  Response will be de fined as <1% decrease in weight or a decrease 
in the number of stools at the Week 8, Week 16,  Week 24, Week 32 and Week 40 visit compared 
to Day 0 baseline values.  We will also evalu ate the change in immunologic laboratory parameters 
such as decreases in inflammatory cytokines and biomarkers that appear to play a role in disease 
pathogenesis at the Week 48 study point.   
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 12 
PRÉCIS 
The purpose of this study is to assess the safety/tolerability and efficacy of using ustekinumab in 
subjects with common variable immunodeficiency CVID or selective IgG subclass deficiency 
(functional agammaglobulinemia) who have associated symptomatic gastrointestinal 
inflammation (CVID enteropathy). Ustekinumab (a Food and Drug Administration [FDA] approved drug) is a monoclonal antibody to in terleukin (IL)-12/23p40. CVID is a clinically 
heterogeneous disorder characteri zed by [CONTACT_673377]. In 
addition to chronic or recurrent pyogenic sino-pul monary infections, many patients develop non-
infectious gastrointestinal manif estations that can be disabling or fatal. Currently there is no 
standard therapy for the associated gastrointes tinal disease outside of empi[INVESTIGATOR_673335], anti-diarrheal ag ents, and non-specific anti-inflammatory agents. 
Recently, gut inflammation complicating functi onal hypogammaglobulinemia due to CVID and 
selective IgG subclass deficiency has been characterized as a T he lper type 1 (Th1) inflammatory 
response, with excess IL-[ADDRESS_909895] specific anti-IL-12 
therapy in this patient group.  It has been pr eviously shown that therapy targeted to IL-12 
successfully treated the Th1 gut inflammation of Crohn’s disease (CD). Ustekinumab, a 
monoclonal antibody to the p40 subunit of IL-12 and IL-23, is FDA approved for the treatment of 
moderate to severe plaque psoriasis, active psoriatic  arthritis, and more recently, moderately to 
severely active CD. This protocol is designed to  measure the safety of ustekinumab in patients 
with functional hypogammaglobulinemia and CVID enteropathy, as well as measure effects on symptoms, gut function, expression of immune cell  surface markers, production of cytokines and 
global gene expression from blood and gut mucosa l mononuclear cells, and the gut microbiota. 
Patients with CVID and selective IgG subclass deficiency with gastrointestinal symptoms of 
malabsorption, maldigestion, and chronic diarrhea will be enrolled into this study. Subjects (up to a total of 10 individuals) will receive a treatmen t dose of 270 mg (3 doses of 90 mg either single-
use prefilled syringe or single-use vial, depending on availability) will be injected subcutaneously 
in subjects by [CONTACT_673370] [ADDRESS_909896]-treatment, these include 
upper and/or lower endoscopi[INVESTIGATOR_014], to measure changes in immune responses and studies to evaluate 
physiologic measures of gut function at 48 weeks, as well as routine safety monitoring throughout 
the study. Gut absorption tests will be performed at  the Week 24 visit. Variables will include safety 
(adverse event rate), clinical (weight, stool fre quency, results of gut absorption tests), and 
laboratory (lymphocyte and cytokine assays) parameters for descrip tive summary statistical 
analysis (n, mean, median, standard deviation, minimum and maximum range). 
 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 13 
1.0 INTRODUCTION 
1.1 C OMMON VARIABLE IMMUNODEFICIENCY (CVID) 
Common variable immunodeficiency (CVI D) is characterized by [CONTACT_673378] a primary failure of B cell differentiation and impaired secretion 
of immunoglobulins. This is frequently accompanie d by T cell abnormalities consisting of blunted 
proliferative responses to mitogenic and antigenic stimuli, a relative lack of mature (CD45RO) T cells, and reduced production of IL-[ADDRESS_909897] CVID is encountered as sporadic and not as inherited disease (Grimbacher et al., 2003; Salzer et al., 2005) .  The major manifestations of this disease include 
bacterial infections, autoimmune diseases (i.e ., autoimmune hemolytic anemia, idiopathic 
thrombocytopenic purpura, and pernicious anemia), and an increased risk for lymphoproliferation 
and neoplasia. In addition, it has been descri bed that patients with selective IgG subclass 
deficiency can also manifest similar infections and autoimmune disease (Martinot et al 2014; 
Quinti et al 2011; Geha 1988; Umetsu et al 1985) . In addition, prior studies have indicated that 
selective deficiencies not only in IgG2 or IgG4, bu t also IgG3 can lead to decreased responses to 
capsular polysaccharide of Haemophilus influenz a type B (Hib) and were associated with 
increased incidence of pneumonia in children (Umetsu et al. 1985).  Finally, autoimmune 
cytopenias (i.e. neutropenia and idiopathic thrombocytopenia) which can commonly occur in 
CVID can also occur in selective IgG subclass deficiency (Sugita et al 1993).   
Therapy for these conditions is aimed primarily at restoring immunoglobulin levels with the 
administration of intravenous pooled immunoglobulin  (IVIG) (Quinti et al 2011).  While this 
therapy clearly decreases the fre quency and severity of infections , it has no effect on associated 
autoimmune disease or neoplasia risk.  Furthermore, it  is recognized that the GI tract is affected in 
CVID not only by [CONTACT_673379], which are unresponsive to IVIG therapy. For the purposes of this protocol, both CVID and selective IgG subclass de ficiency will be termed CVID or functional 
hypogammaglobulinemia. 
While the hallmark of CVID is the inability to make  antibodies to specific antigens, this has been 
attributed to abnormalities in both B and T cel l status and function. Low B cell (CD19+) numbers 
(in 5-10% of CVID patients) are associa ted with failure to produce antibodies in vitro  (Farrant et 
al., 1994 ), and the majority of CVID patients with normal B cell numbers are lacking in mature 
class-switched B cells (i.e., CD27+IgM-IgD- memory B cells) (Warnatz et al., 2002; Jacquot et 
al., 2001) . This latter observation is consistent with the lack of plasma cells (particularly those 
producing class-switched antibodies, as CD27 is known to promote interaction with T cells for 
differentiation into plasma cells) in the lamina propria ( Herbst et al., 1994; Washington et al., 
1996) . Additionally, among those with normal B cell numbers, B cells may be induced in vitro  to 
produce IgM alone, IgM and IgG, or remain unresponsive (Bryant et al., 1990 ) suggesting the 
mechanism for producing antibodies is not due to primary B cell defects in some patients. 
Furthermore, selective IgG subclass deficiency (i .e. IgG2 subclass deficiency) can also manifest 
associated poor antibody response to antigen chal lenge (polysaccharide antigen) similar to CVID 
patients (Geha et al. 1988).  CVID patients with near normal numbers of mature class-switched B 
cells (CD27+IgM-IgD-) seem to be the ones who can produce IgM and IgG in vitro  (those with 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 14 
low numbers of mature class-switched B cells can be further defined by [CONTACT_673380] a 
concomitant excess of immature B cells (CD21-) (Warnatz et al., 2002) . However, any such 
classification of B cell dysfunction does not se em to clearly predict the natural history or 
development of complications in CVID.   
T cells in CVID patients have been variously  reported to display reduced proliferation and 
activation by [CONTACT_673381]/or mitogens (Cunningham-Rundles and Bodian, 1999; Fischer et al., 
1993; Fischer et al., 1994; North et al., 1991),  have impaired IL-2 production, show lower 
expression of cell surface CD40L (Brugnoni et al., 1996; Farrington et al., 1994 ), fail to develop 
antigen-specific responses (Kondratenko et al., 1997; Stagg et al., 1994) , and show excessive 
activity of CD8+ cells (Jaffe et al., 1993; North et al., 1998; Serrano et al., 2000; Wright et al., 
1990; Waldmann et al., 1974) . Although antigen-presentation appears to be intact for CVID 
monocytes and macrophages (Gupta and Damle, 1983; Thon et al., 1997) , dendritic cells and 
monocytes may have altered cytokine production th at could affect the function and differentiation 
of B cells (Cambronero et al., 2000; Cunningham-Rundles and Radigan, 2005) . In sum, the variety 
of the altered cellular immune response observed in CVID lymphocytes supports the notion that failure to produce antibodies may be a primary B cell defect but more likely is contributed to by 
[CONTACT_673382] T cell signals and interactions.    
1.1.[ADDRESS_909898] othe r conditions that can complicate functional 
hypogammaglobulinemia including autoimmune diseases (cytopenias, hypothyroidism) 
(Cunningham-Rundles and Bodian, 1999) , nodular lymphoid hyperplasia (NLH) of the intestinal 
mucosa, lymphoma, and an enteropathy presenting as chronic diarrhea and malabsorption.  
Patients with CVID are more susceptible to protozoan and bacterial gast rointestinal pathogens. 
Infection with Giardia lamblia  is frequently encountered and is characterized by [CONTACT_673383]. In additi on, there is an increased inciden ce of infections with common 
gastrointestinal pathogens (e.g., Salmonella , Shigella , and Campylobacter species). Severe 
diarrhea has been associated with the fastidious gram-negative rod known as dysgonic fermenter-3 (DF-3) (Wagner et al., 1988) . While the incidence of Giardia  infection has decreased 
significantly in patients on chronic IVIG therapy (Teahon et al., 1994) , the rate is still higher than 
seen in normal individuals.  
In addition to protozoan and bacterial gastrointes tinal pathogens CVID patient population can be 
at risk for viral pathogens. The most commonly reported being rhinovirus and norovirus. The former involving predominately the respi[INVESTIGATOR_673336] a reported rate of incidence of norovirus at 8% in a study population which included 
CVID and X-linked agammaglobulinemia patients (Duraisingham et al. 2015). Whether norovirus gastrointestinal infection impact s upon gastrointestinal malabsorption in this patient population is 
not apparent. Patients with immunodeficiency are observed to have prolonged clearance of this 
organism and can have chronic shedding of the vi rus.  However, only patients with significant T 
cell impairment (status post bone marrow or ca rdiac transplant) have displayed prolonged 
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909899] been 
treated with oral preparations of immunoglobulin w ith small success in clearance of this organism 
(Duraisingham et al. 2015, Green 2014, Masclee et  al. 2013, Nelson et al 2013, Kolho et al 2012 
Florescu et al 2011, O’ Connor  et al 2009).  
1.1.2 Gastrointestinal Manifestations of CVID 
Gastrointestinal (GI) manifestations of CVID unre lated to infections occur in upwards of 20% of 
patients ( Cunningham-Rundles and Bodian, 1999 ; Sneller et al., 1993, Mannon et al 2006 ). This 
is most likely an underestimate since patients without overt ga strointestinal symptoms are not 
routinely examined for gut abnormalities. Patients  with this syndrome, termed CVID enteropathy, 
exhibit villous atrophy of the small bowel muco sa and a complex of associated symptoms 
including chronic diarrhea, malabsorption marked by [CONTACT_673384], and protein-losing 
enteropathy leading to loss of albumin and other prot eins into the fecal stream. These symptoms 
can lead to severe weight loss, hypoalbuminemia pr edisposing to edema, and the need for nutrient 
supplementation ( Mannon et al 2006 ). 
In one study, 51% (22/43) of patients with CVID  had accompanying GI symptoms (i.e., chronic 
or bloody diarrhea, documented Giardia  or other parasitic infe ction, pernicious anemia, 
pneumatosis coli, malabsorption, and perirectal absc ess) and of those with gut tissue examined 
histologically (10/22), 100% had striking abnormalities (Washington et al., 1996) . A wide range 
of histologic abnormalities are seen: in the st omach, morphologic changes consistent with acute 
graft-versus-host disease (apoptotic glandular epi[INVESTIGATOR_1663], dense mononuclear inflammatory 
cell infiltrate with occasional crypt obliteratio n), increased intraepi[INVESTIGATOR_673337], and 
varying degrees of gastritis (leading in some cas es to atrophy and achlorhydria in the absence of 
Helicobacter pylori  infection and anti-parietal cell a nd anti-intrinsic factor antibodies (Moriuchi 
et al., 1990; Twomy et al., 1970; Wright and Sears, 1987; Zullo et al., 1999)) ; in the small intestine 
histologic changes include mild to marked vill ous atrophy (differing from celiac sprue by [CONTACT_673385], lack of significant basal crypt hyperplasia, and relatively normal enterocyte maturation with preserve d brush border and Goblet cells), increased 
intraepi[INVESTIGATOR_673337], nodular lymphoid hyperplasia (NLH), frank lymphomatous changes as well as the occurrence of non-granulomatous tran smural inflammation with evidence of fibrosis 
and strictures (Teahon et al., 1994; Washington et al., 1996) ; finally in the colon there can be 
inflammation that resembles lymphocytic colitis (with increased lymphocytes in the surface 
epi[INVESTIGATOR_2130]), ulcerative colitis (with acute inflammatory cells in the crypt epi[INVESTIGATOR_673338], and loss of crypts in severe disease, but lacking the plasma cell infiltrate seen in classical ulcerative colitis), or graft-versus-host dis ease. One study notes Crohn’s disease, and ulcerative 
colitis/proctitis associated with CVID (Cunningham-Rundles  and Bodian, 1999) , but other more 
detailed studies of the accompanying enteropathy do  not support its meeting the full histologic 
criteria for these diseases ( Teahon et al., 1994 ; Washington et al., 1996 ). 
The lesions of intestinal nodular lymphoid hy perplasia (NLH) are said to be virtually 
pathognomonic for CVID, but NLH does occur rarely in otherwise normal individuals. These 
macroscopic collections of lymphocytes are found primarily in the small bowel and sometimes in 
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909900] of which are CD8+ 
(van den Brande et al., 1988)  suggesting they are attempts to form productive B cell follicles that 
are not properly down-regulated by T cells.  Whil e not the source of symptoms themselves, they 
may be associated with an increas ed risk of intestinal lymphoma (Castellano et al., 1992; Ryan, 
1996) .    
The gut inflammation and histologic changes accomp anying CVID are not related to the presence 
of intestinal infections, although bacterial overgr owth and infection with pathogenic bacteria and 
parasites should be evaluated and treated as a cause of gastrointestinal symptoms. The enteropathy 
does not respond to antibiotic or IVIG therapy. Ins tead it has been suggested that the gut lesions 
could reflect autoimmune enteritis ( Teahon et al., 1994; Washington et al., 1996).  Although 
autoimmune enteritis occurs in young childre n and generally not adults, only one case report 
documents the characteristic anti-enterocyte antibodies (Catassi et al., 1988)  in a boy with CVID, 
and another report notes that 58-67% of patients with CVID and gastrointestinal symptoms also 
have other possible autoimmune diseases (aut oimmune hemolytic anemia, thrombocytopenia with 
antiplatelet antibodies, neutropenia, arthritis, th yroid dysfunction, pernicious anemia, vitiligo, 
epi[INVESTIGATOR_227], and insulin-dependent diabetes mellitus) ( Washington et al., 1996 ). A plausible 
immunologic mechanism for the enteropathy is th e presence of a T cell dysfunction leading to 
autoimmune attack within the intestinal wall. Such a role for T cell dysfunction in CVID is consistent with the observation that the enteropathy does not occur in X-linked 
agammaglobulinemia, an immunodeficiency state w ith impaired B cell function equal or greater 
than CVID but with no accompanying T cell abnormality (Lederman and Winkelstein, 1985) . 
Furthermore, CVID patients with related enteropathy  are more likely to have T cell dysfunction 
than those without ( Cunningham-Rundles  and Bodian, 1999 ). Even the morphologic changes 
suggest a primary role for T cells in the enterop athy, with T cells predominating in the lamina 
propria infiltrate and the epi[INVESTIGATOR_673339]-versus-host disease that is 
mainly T cell-mediated. 
Finally it should be stated that there is no standa rd treatment that ameliora tes the gastrointestinal 
disease in CVID patients. Therapeutic inte rventions for weight loss are aimed at 
hyperalimentation, including total parenteral nutrition when indicated, and identifying any 
treatable causes of malabsorption such as small bowel bacterial overgrowth. The approach to chronic diarrhea is little different than in ot her immunodeficient patients, with an emphasis on 
ruling out treatable infectious etiologies. The gu t inflammation can be treated with non-specific 
anti-inflammatory agents, but none have shown co nsistent efficacy in this patient population. 
1.1.[ADDRESS_909901] an abnormally low CD4/CD8 ratio (<0. 9), and an increased incidence of splenomegaly 
(71%) and anergy (42%) compared to CVID patients with normal CD4/CD8 ratios (29% and 7%, respectively) (Wright et al., 1990) . The low CD4/CD8 ratio in this CVID group is due to an 
increase in CD8+ cells, which have impaired proliferation but secrete increased levels of IFN J and 
IL-5 (but normal amounts of IL-4) when stimulated in vitro  (Jaffe et al., 1993 ; Wright et al., 1990 ). 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 17 
In these studies the CD4+ cells behaved normally, and in only the occasional patient could CD8+ 
effects potentially explain the hypogammaglobulinemia.  
In another study of 24 CVID patients, low CD 4+ cell counts and a low CD4/CD8 ratio < 0.9 was 
observed that could not be attributed to an expanded CD8+ population (Aukrust et al., 1996) . In 
addition, this study group had significantly elevated serum TNF alpha levels which was 
particularly evident in the subset (11/24 patients ) defined by [CONTACT_493165], a CD4+ count < 400 
x 106/L, and significantly elevated serum neopterin  levels. Furthermore, another report showed 
that significantly more peripheral blood monocytes  (CD14+, but not CD14- cells in a dendritic cell 
pool) from CVID patients expressed high IL-12 following lipopolysaccharide (LPS) stimulation 
than normal controls or patients with X-linked agammaglobulinemia ( Cambronero et al., 2000 ); 
this was associated with significantly increased expression of IFN J in CD4+ (and CD8+) T cells.  
A more recent study confirmed the lack of IL -12 production in CVID dendritic cells (CD14-) 
compared to its induced production in normal s, but other monocytes were not studied 
(Cunningham-Rundles and Radigan, 2005) . Lastly, in CVID patients with granulomatous disease 
or reduced numbers of class-switched memory B cells, plasmacytoid dendritic cells (promoting Th2 responses) were disproportionately decreased co mpared to myeloid dendritic cells (promoting 
Th1 responses), suggesting a possible bias toward Th1 inflammatory responses (Viallard et al., 
2005) . While it is not known whether gastrointestin al disease is experienced  at a higher rate in 
high-TNF or any of these other CVID subsets , given the role of TNF in gut granulomatous 
inflammation and its role in Crohn’s disease, these data sup port the idea that immune activation, 
with a Th1 skewness, may be associated with gast rointestinal disease in CVID.  Clearly excess 
TNFD can contribute to gastrointestinal inflammatory states as seen in transgenic animal models 
(Kontoyiannis et al., 1999)  and in the beneficial response of human Crohn’s disease to TNF D 
immunoneutralization.   
 
 
Figure 1: IL-12 secretion from LPMCs isolated from endoscopic biopsies of the 
duodenum and colon in CVID patients with or without chronic diarrhea 
or weight loss. 
 

Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 18 
1.1.4 Preliminary Data in CVID Enteropathy 
To evaluate the immunopathogenesis of CVID ente ropathy we previously conducted an extensive 
comparison of the absorptive capacity and cyt okine response of CVID patients with 
gastrointestinal symptoms and those with such  symptoms. We observed that patients with 
gastrointestinal symptoms had evidence of metabo lic dysfunction, which consisted of lower body 
mass index associated with an inability to absorb carbohydrates and proteins. Microscopic examination of tissue from symptomatic CVID patien ts exhibited diffuse histologic inflammatory 
changes in both the duodenal mucosa and sometimes the colonic mucosa as well.  This included 
villus blunting, increased lamina propria and intraepi[INVESTIGATOR_673340] (devoid of plasma cells), and epi[INVESTIGATOR_673341].   
In addition, in immunologic studies, purified lamina propria mononuclear cells (LPMC) obtained 
from symptomatic CVID patients displayed a signif icantly higher IL-12-me diated T-helper (Th) 1 
cytokine response (Figure 1) accompanied by [CONTACT_673386] J secretion. However, 
compared with the cytokines produced by [CONTACT_673387]'s disease (CD), cells from CVID patient cells did not produce excess amounts of the T h17 cytokines, interle ukin-23, interleukin-17, 
or increased amounts of TNF- D. Thus, these studies indicated that CVID enteropathy was 
accompanied by [CONTACT_673388]-12-mediated Th1 T cell cytokine production, distinct from that 
observed in Crohn’s disease patients by [CONTACT_673389]17 response. Interestingly, only 
CVID patients with gastrointestinal symptoms of diarrhea and weight loss as well as the gut 
inflammatory changes had this excess cytokine produc tion.  CVID patients with similar histologic 
findings but no symptoms had no in creased cytokine production ( Mannon et al, 2006 ).  
 IL-12 therefore is a notable contributor to inflamma tion, thus it is reasonable to believe that IL-
12 blockade in CVID enteropathy patients shou ld lead to a decrease in gut inflammation and 
subsequent improvement of gastrointestinal symptoms ( Trinchieri G, 1998 ). Thus, CVID patients 
in Cohort 1 (n=3) have received a single subcutan eous dose administration (270 mg 3.9 mg/kg for 
a typi[INVESTIGATOR_2855] 70 kg patient) of ustekinumab. All pati ents have demonstrated  improvement  in stool 
pattern and [ADDRESS_909902] had observable weight gain (range of 1.7 kg to 5 kg above baseline 
weight). No patient experienced any significant and/or unanticipate d adverse events or infectious 
pathogen complications (see a ppendix G - Cohort 1 Single Dose Study Adverse Events).  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 19 
1.2 S TUDY AGENT  
Usktekinumab (Stelara ®, Janssen Biotech, Inc) is a human IgG1kappa monoclonal antibody to 
the p40 subunit of IL-12 and IL-23. It has an approximate molecular weight of 148,600 daltons.  
Figure 2:  Usktekinumab 
 
Ustekinumab inhibits the bioactivity of human IL-12 and IL-23 by [CONTACT_673390]-12Rbeta1 receptor protein expressed on the surface of immune cells. Ustekinumab has shown efficacy in trials for the treatment of moderate-to-severe plaque psoriasis, 
and was approved by [CONTACT_673391] (FDA) in 2009 for the treatment of adult 
patients with moderate to severe plaque psoriasis  who are candidates for phototherapy or systemic 
therapy.  It is FDA approved for the treatment of adult patients with active psoriatic arthritis and 
more recently, in Sepetember 2016, ustekinumab ha s been approved for the treatment of patients 
with Crohn’s disease. Ustekinumab is available for subcutan eous injection as either pre-filled 
syringes (45 mg/0.5 mL or 90 mg/1 mL), or a single-use vial (45 mg/0.5 mL dose, 90 mg/1 mL.  Ustekinumab is also available as 130 mg/26 mL (5 mg/mL) for intravenous (IV Crohn's disease 
induction dosing. Dosing recommendations for plaque  psoriasis are 45 mg administered at weeks 
0 and 4, and then every 12 weeks; 90 mg ca n be used alternatively if the patien t’s body weight 
exceeds 100 kg (Stelara
® Data Sheet, Appendix B ).  Dosing recommendations for Crohn’s disease 
are 260 mg (patients less than 55 kg), 390 mg (pat ients 55 to 85 kg) and 520 mg (patients > 85 kg) 
IV administration at week 0 and then 90 mg subcutaneous every 8 weeks.  

Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 20 
1.3 P HARMACOKINETICS  
Pharmacokinetic data is available for the use of ustekinumab in the treatment of psoriasis. See 
attached Stelara® Data Sheet (drug insert), Appendix B . 
1.4 C LINICAL EXPERIENCE IN CROHN ’S DISEASE  
Crohn’s disease (CD) is thought to be a T-helper type 1 (Th1) mediated inflammation, with IL-12 
and IL-23 playing major roles ( Sandborn, 2008; Sandborn, 2012 ).   In addition, CD is characterized 
by a chronic inflammation of the gut mucosa leading to  weight loss and diarrhea. CD patients with 
moderate to severe disease are also relatively immunosuppressed and more susceptible to infection 
than the general population due to the medications used to treat the disease. In both CD and CVID enteropathy patients an increased production of IL- 12 is found in stimulated cytokine assays of 
LPMCs ( Mannon et al, 2006 ). Therefore, CD serves as a comparable population to CVID 
enteropathy when assessing the potential benefits and risks of anti-IL-[ADDRESS_909903] published report of the use of a monoclona l antibody to IL-12/23p40 in CD described the 
results of a double-blinded randomized control tr ial. CD patients who received 3 mg/kg 
intravenous drug for 7 weeks had a 75% rate of res ponse as compared to 25% in the placebo group 
(p=0.03) at the primary endpoint. In addition, pa tients who demonstrated clinical improvement 
from anti-IL-12/23p40 therapy had a decr ease in the production of IL-12, IFN J, and TNF
D. There 
were no significant differences in the rate of a dverse events between placebo and study drug groups 
other than local injection site reactions, which were mostly mild and transient ( Mannon et al, 
2004 ).   
In previous phase II studies, ustekinumab has also been shown to be safe and effective in treating 
moderate-to-severe CD refractory to anti-t umor necrosis factor (anti-TNF) treatment.  
In 2008, the results of a double-blind, cross-over tr ial comparing placebo, subcutaneous (SC), and 
intravenous (IV) dosing regimens of ustekinumab in patients with moderate-t o-severe CD revealed 
that overall ustekinumab was more likely to i nduce response than placebo (53% vs 30%, p=0.02) 
at 4 and 6 weeks. Comparison between IV and SC dosing regimens showed that a single IV 
treatment dose had a trend towards higher rate of response versus multiple SC doses. There were 
no increased adverse events in the treatment grou p when compared to placebo (Sandborn et al, 
2008). In a follow-up Phase IIb study of ustekinumab in CD patients who have failed anti-TNF therapy demonstrated that a 6 mg/kg IV treatmen t dose was significantly better than placebo in 
inducing clinical response (39.7% vs. 23.5%, p=0.005) at  the 6 week endpoint. In addition, patients 
who did not respond to the placebo dose were give n a SC treatment dose of 270 mg, with a clinical 
response rate of 35.3%. One patient who received 1 mg/kg of ustekinumab reported a basal-cell 
carcinoma that was resected. The relation of the basal-cell carcinoma to therapy was not 
commented on in the paper. Otherwise, there were  no significant differences in rate of adverse 
events between groups ( Sandborn et al, 2012 ).  
Finally, in two phase 3 trials to evaluate the ef ficacy of ustekinumab in moderate to severe CD, 
patients, patients who could not tolerate or had an inadequa te response to one or more TNF 
inhibitors  (UNTI-1) were randomized to receive a single IV dose of 130 mg, a weight-based IV 
dose or placebo. For the weight based dosing, pati ents who weighed 55 kg or less received 260 mg 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 21 
of ustekinumab; patients who weighed between 55  and 85 kg received 390 mg; and patients who 
weighed more than 85 kg received 520 mg. The primary endpoint was clinical response  (decrease 
of CDAI of 70 points or greater) at week 6. The trial reached its primary endpoint yielding a 
clinical response rate at week 6 of 34% (P=0.03) in the 130 mg and weight based ustekinumab treated patient population as compared to pla cebo arm (21.5%). Clinical remission at week 8, 
defined by a CDAI score of less than 150, was a secondary endpoint. This  endpoint was reached 
with remission rates of 16% and  20.9% (P<0.001) in the130 mg and weight based ustekinumab 
treated patients respectively as compared to the placebo arm (7.3%) (Lichtenstein G, 2016). In 
another randomized placebo controlled trial (UNTI- 2) patients with moderate to severe CD who 
could not tolerate or had an inad equate response to corticosteroids , at least one immunomodulator, 
or both or had had never been  treated with a TNF inhibitor were randomized to receive a single IV 
dose of 130 mg, a weight-based IV dose or placebo. The trial reached its primary endpoint yielding 
a clinical response rate at week 6 of 52% (P=0.03)  in the 130 mg and 56% in the weight based 
ustekinumab treated patient population as compared  to placebo arm (29%). Clinical remission at 
week 8, defined by a CDAI score of less than 150, was a secondary endpoint. This endpoint was 
reached with remission rates of 30% and 40 % (P<0.001) in the 130 mg and weight based 
ustekinumab treated patients respectively as comp ared to the placebo arm (20%) (Lichtenstein G, 
2016). Furthermore, in a maintenance trial (IM-UN TI), patients who had achieved a clinical 
response to ustekinumab after 8 weeks were ra ndomized to receive maintenance treatment 90 mg 
SC every 8 or 12 weeks. After 52 weeks, 53% of patients who had received ustekinumab every 8 
weeks and 49% of those patients that had receive d ustekinumab every 12 weeks were in remission, 
as compared to 36% of those that had received placebo (Lichtenstein G, 2016). 
1.5 R
ATIONALE FOR DOSE SELECTION  
Ustekinumab has been studied previously for the treatment of CD, which has a similar cytokine 
profile to CVID enteropathy. In those studies a treatment of 270 mg was given as a single 
intravenous (IV) dose and was found to be more ef fective than multiple subcutaneous (SC) doses 
in inducing a clinical response. On these studies, the highest dose tested, (6 mg/kg IV) had the highest rate of response. In addition, the single SC dose of 270 mg was also tested as a crossover treatment for those patients who did not respond to placebo treatment. Rate of response for the 
single 270 mg SC treatment was similar to th e 6 mg/kg IV dose (35.3% vs. 39.7%, respectively). 
No increased rate of infection or other adverse ev ents were found in any previous studies of CD 
patients at any of the studied dosages. A higher incidence of arthralgia, nausea, and dental 
infections was observed in STELARA
®-treated patients when compared with placebo-treated 
patients (3% vs. 1% for arthralgia and 3% vs. 1%  for nausea; 1% vs. 0.6% for dental infections) 
in the placebo controlled portions of  clinical trials (Stelara® Data Sheet, Appendix B ).  
In this study, CVID patients in Cohort 1 (n=3) have received a single subcutaneous dose 
administration (270 mg 3.9 mg/kg for a typi[INVESTIGATOR_2855] 70 kg  patient) of ustekinuma b. All patients have 
demonstrated improvement in stool  pattern and abdominal discomfort with 2 patients having 
observable weight gain (range 1.7 to 5 kg above baseline weight). No patient experienced any 
significant and/or unanticipated adverse events or infectious pathogen complications. Two patients 
have completed study (and one patient shortly in December 2016) at [ADDRESS_909904] been released (October 2016) 
as 260 mg (patients less than 55 kg), 390 mg (patients 55 to 85 kg) and 520 mg (patients > 85 kg) 
IV administration at week 0 and then 90 mg subcutaneous every 8 weeks.   Thus, based upon responses in CVID patient coh ort 1 and recommended dose administration for 
CD patients CVID patients will receive a 270 mg  subcutaneous loading dose and then receive 90 
mg subcutaneous every 8 weeks (for a total of five 90 mg doses).   CVID patients enrolled in this study have existi ng cachexia and weight loss with body weight 
approximately 55-65 kg range. Therefore the initial dose of 270 mg previously used in CD patients 
and in Cohort 1 CVID patients represents a scientifically sound and reasonable balance between 
safety and efficacy and minimizing the risk of immunosuppression in an already immunocompromised population.  Finally, IV dose vials (130 mg/26 mL) are to be released 
however, the 90 mg/mL concentration for subcutane ous administration is available and will be 
used for the continued study. 
2.[ADDRESS_909905] ration of ustekinumab in CVID enteropathy 
patients by [CONTACT_673372].  
2.2 S ECONDARY OBJECTIVES  
 
x To assess the efficacy of the study agent in alleviating symptoms of CVID enteropathy by 
[CONTACT_673392] 8, Week 16, Week 24, Week 
32, Week 40, and Week 48 with Day 0 baseline values. 
x To assess changes in gut absorption and protein loss (D-xylose absorption, 48 hour stool fat 
collection, fecal alpha-1 antitrypsin (A1AT)  clearance) at Week 24 and Week 48 by 
[CONTACT_673374]. 
x To assess changes in mucosal histolog y score (modified D’haens scoring) at Week 48 by 
[CONTACT_673375].  
x To measure changes in stimulated cytokine  production and mRNA expression microarray by 
[CONTACT_673393] 48 by [CONTACT_673374].  
x To measure changes in gut microbiota and glob al gene expression of inducible interferon and 
metabolic genes in LPMCs at Week 48 by [CONTACT_673374]. 
x To measure changes in laboratory surrogate efficacy markers of inflammatory bowel disease 
treatments (C-reactive protein [CRP], erythro cyte sedimentation rate [ESR], albumin, 
hemoglobin, platelets) at Week 8, Week 16, Week 24, Week 32, Week 40 and Week 48. 
3.0 STUDY DESIGN AND METHODS 
This is an open-label study in CVID or se lective IgG subclass deficiency (functional 
agammaglobulinemia) patients with active gastrointestinal symptoms (CVID enteropathy). Up to 
10 eligible adult subjects will be enrolled at th e NIH Clinical Center. This study consists of a Pre-
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 23 
Treatment Visit (Day -120 to -1), a Treatment Vi sit (Day 0), a Week 8  Tr eatment Visit, a Week 
16 Treatment Visit, Week 24 Treatment Visit, We ek 32 Treatment Visit, Week 40 Treatment Visit 
and a Week 48 Endpoint Visit.  A treatment dose of 270 mg (3 doses of 90 mg either single-use 
prefilled syringe or single-use vial, depending on avai lability) will be injected subcutaneously in 
subjects by [CONTACT_673370] 0 stud y visit. Subjects will then receive a follow up 
Treatment dose of 90 mg (1 dose of 90 mg) at Week 8, Week 16, Week 24, Week 32, and Week 40. Patients will be evaluated at Week 8, W eek 16, Week 24, Week 32, Week 40, and Week [ADDRESS_909906] already received a single 27 0 mg dose may be eligible for retreatment as 
follows: A treatment dose of 270 mg (3 doses of 90 mg ei ther single-use prefilled syringe or single-
use vial, depending on availability) will be injected  subcutaneously in subjects by [CONTACT_673394] 0 study visit. Subjects will then receive a follow up treatment dose of 90 mg (1 
doses of 90 mg) at Week 8, Week 16, Week 24, W eek 32, and Week 40. These subjects will be 
classified as Cohort [ADDRESS_909907] number to prevent any 
confusion of the new data with the data previ ously collected from the single-dose study. 
Newly enrolled subjects will be assigned into Cohort 2 and will receive ustekinumab doses as 
follows: A treatment dose of 270 mg (3 doses of 90 mg ei ther single-use prefilled syringe or single-
use vial, depending on availability) will be injected  subcutaneously in subjects by [CONTACT_673394] 0 study visit. Subjects will then receive a follow up treatment dose of 90 mg (1 
dose of 90 mg) at Week 8, Week 16, Week 24, Week 32, and Week 40.  
3.1 S
TUDY ENDPOINTS  
3.1.1 Primary Endpoint 
The primary endpoint of the study is whether treatm ent with ustekinumab is safe and tolerated in 
CVID enteropathy patients and does not cause a sign ificant increase in infection or result in any 
serious adverse events (SAEs) that are determined  to be definitely, probably or possibly related to 
administration of the study agent. 
3.1.2 Secondary Endpoint 
The secondary endpoint of the study is whethe r patients respond to the treatment with 
ustekinumab.  Response will be defined as <1% d ecrease in weight or a decrease in the number of 
stools at the Week 8, Week 16, Week 24, Week 32 and Week 40 visit compared to Day 0 baseline 
values. We will also evaluate the change in im munologic laboratory parameters such as decreases 
in inflammatory cytokines and biomarkers that appear  to play a role in disease pathogenesis at the 
Week 48 visit. 
4.0 INCLUSION AND EXCLUSION CRITERIA 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 24 
4.1 D IAGNOSIS AND CRITERIA FOR INCLUSION : 
A subject is eligible for the study if all of the following criteria are met: 
x Has given written informed consent. 
x Is male or female aged 18 through 75 years. 
x Has CVID or selective IgG subclass defi ciency of either one or concomitant IgG 
subclasses comprising IgG1, IgG2, IgG3 or IgG4 (functional hypogammaglobulinemia) 
diagnosed prior to screening as based on the International Union of Immunological Societies (IUIS) criteria. ( Chapel et al., 2003; Martinot et al 2014; Quinti et al 2011; 
Geha 1988; Umetsu et al 1985; Sugita et al. 1993)  
x Has a documented, unintended loss of >5% of their body weight over the last year or 
requires nutritional supplements to maintain his/her body weight and/or  has chronic 
diarrhea defined as a complaint of at >/= 50% of stools are non-formed for at least [ADDRESS_909908] be dependent on a therapeutic dose of antidiarrheals (e.g., loperamide or diphenoxylate with atropi[INVESTIGATOR_050]) for control of chronic diarrhea. 
x If taking oral antibiotics chronically, must have used a stable dose of the antibiotic 
continuously for at least [ADDRESS_909909]’s circumstances (e.g. fertility status, medical contraindications to hormonal birth control, 
and/or personal or religious beliefs regardi ng pregnancy avoidance).  Subject to the 
judgment and discretion of the PI, some subjects may not need to take pregnancy 
avoidance measures (see Appendix F).  Appendix F, patient handout on pregnancy avoidance will be provided to patients at the time of consent and discussion regarding pregnancy avoidance during the study. 
x Subjects who have previously been treated with a single [ADDRESS_909910] be > [ADDRESS_909911] had recurrence of 
enteropathy symptoms. 
4.2 C
RITERIA FOR EXCLUSION : 
A subject is excluded from the study if any of the following criteria are met: 
General Criteria 
x Has any clinically significant disease or co ndition (e.g., renal, hepatic, neurological, 
cardiovascular, pulmonary, endocrinologic, psyc hiatric, hematologic, urologic, autoimmune 
or other acute or chronic illness) that in the opi[INVESTIGATOR_673342], or put the subject at undue risk by [CONTACT_232642]. 
x Is a woman who has a positive pregnancy test or who is breast-feeding. 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 25 
x Is a woman who does not agree to abide by [CONTACT_3433] e contraceptive measures required to prevent 
pregnancy during participation in the study, or meets exemption criteria for contraceptive 
measures, as outlined in Appendix F. 
x Has any of the following clinical chemistry values: 
o AST >2.5 x upper limit of normal (ULN). 
o ALT >2.[ADDRESS_909912]. 
o Serum bilirubin >1.[ADDRESS_909913]. 
o Serum creatinine >1.[ADDRESS_909914]. 
o Alkaline phosphatase >2.[ADDRESS_909915]. 
x Has a hemoglobin level <9 g/dL or hematocrit <30%. 
x Has an International Normalized Ratio (INR) > 1.3 or a Partial Thromboplastin Time (PTT) >[ADDRESS_909916]. 
x Has the following cell counts (cells/ μL): 
o Platelet count <75,000 or >800,000. 
o White blood cell count <2,000. 
o Neutrophil count <1,000. 
x Has a current infection requiring intravenous antibiotics, a serious local infection (e.g., 
cellulitis, abscess) or systemic infe ction (e.g., pneumonia, septicemia). 
x Has a history of cancer within the past [ADDRESS_909917] 5 years. 
x Has a history of active tuberculosis (TB) (or a chest x-ray (CXR) with findings suggestive of 
old TB infection including calcified nodular lesions, api[INVESTIGATOR_18304], or pleural scarring), acute or chronic hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or opportunistic 
infections.  
Gastrointestinal Criteria 
x Has a stool sample determined positive for acute gastrointestinal infection with impact of 
occurrence on gastrointestinal inflammation as determined by [CONTACT_22660] [INVESTIGATOR_673343]. In addition, stool samples positive for GI pathogens will be discussed with an 
infectious disease physician to determine impact of occurrence on gastrointestinal 
inflammation.  If organism thought to be pa thogenic, the subject will be treated with 
appropriate therapy.  This will be documented in the subject’s medical record.  
Prior Medication Criteria 
x Received daily corticosteroids within 1 month pri or to receiving study agent. The use of short-
term or single-dose corticosteroids as a pret reatment regimen for IVIG is acceptable. 
x Received any investigational drug within 3 months prior to receiving study agent. 
x Received certolizumab or natalizumab within 3 months prior to receiving study agent. 
x Received vedolizumab, infliximab, etanercept, or adalimumab within 2 months prior to 
receiving study agent. 
x Received cyclosporine, tacrolimus, sirolimus , pi[INVESTIGATOR_031], mycophenolate mofetil or any 
other systemic immunosuppressants within 1 month prior to receiving study agent. 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 26 
4.3 S CREENING AND STUDY PROCEDURES  
Subjects will be screened and may undergo ba seline study procedures under NIH IRB approved 
protocol 89-I-0158 “Immune Regulation in Patients with Common Variable Immunodeficiency.”    
As patients with CVID are already pre-disposed to certain types of infections, all patients will be 
assessed for signs/symptoms of infection at each visi t primarily by [CONTACT_969] (history of cough, fever, 
sinus congestion, etc.), physical (temperature, l ung auscultation, etc.), and safety labs (CBC, 
chemistries, liver function tests).  Further testing w ill be determined by [CONTACT_673395] (blood cultures, ches t x-ray, etc.).  Standard of care treatment and 
follow-up to resolution of infection will be provid ed to the patient, and/or coordinated through 
patient's home physician if required (in cases requiring close local management of therapy, such as intravenous antimicrobial therapy).   
5.0 IMPLEMENTATION 
5.1 S
TUDY POINT 1:  PRE-TREATMENT VISIT - DAY -120  TO -1 
The following screening studies/procedures may be done within [ADDRESS_909918] year, and 
assessment for any signs/symptoms of current infection. 
x Blood Tests:  
o Complete blood count (CBC) with differential 
o PT (Prothrombin Time), PTT (Partial Thromboplastin Time), and INR (International 
Normalized Ratio)  
o Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) 
o Chemistry (acute care panel, mineral panel,  hepatic panel, creatine kinase, lactate 
dehydrogenase, total protein, uric acid) 
o Quantitative Immunoglobulins 
o IgG Subclasses 
o Anti-enterocyte Antibodies 
o HLA testing (to assess DQ2 and DQ8 frequency) 
o Ion Torrent (to assess for CVID-associated genomic polymorphisms, in particular 
TNFRSF13B  and Inducible T-cell Co-stimulator (ICOS)) 
o Assessment of mRNA production in suspected inflammatory pathways by [CONTACT_673396] (research testing on GI biopsies) 
o Global gene expression microarray (research testing on GI biopsies) 
o Human immunodeficiency (HIV) antibody and viral load test 
o Hepatitis panel including Hepatitis B surf ace antigen (HBsAg), hepatitis B e-antigen 
(HBeAg), and Hepatitis C (RNA Quantitative) 
o Quantiferon Gold tuberculosis testing 
x Urine and stool tests: 
o Urinalysis 
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909919] (for females of childbearing potential) 
o Stool sample for GI pathogens (FilmArray GI  Panel testing for 22 viral, bacterial and 
parasitic GI pathogens that cause infectious diarrhea) 
o Stool collections for measurement of fat malabsorption (48 hour fecal fat) and protein 
loss (24 hour A1AT clearance) 
o Stool sample for fecal calprotectin level 
o Stool sample for microbiota research studies 
x Clinical chest CT scan to assess for any clinically significant infection  
x D-xylose absorption study   
x An esophagogastroduodenoscopy (EGD) and/or colonoscopy to be done as an inpatient.  
Colonoscopy pending if evidence of malabsorption and occurrence of bright red blood per rectum, the latter associated with inflammatory disease in the colon. 
o Assess extent and severity of inflammation via photography, biopsy for descriptive 
histopathology (4 to 6 biopsies) and histologic scoring (modified d’Haens score), and 
for collection of LPMCs (up to 30 biopsies) 
o Biopsies from the gut may also be used to study gut microbiota 
x May also include blood collection for the addi tional testing of the following (some or all) 
peripheral blood mononuclear cell s (PBMCs) and LPMC collection from endoscopic biopsies: 
o For CD4+ cells:  Stimulated secretion/production of IL-4, IL-5, IL-6, IL-10, IL-13, 
IL-17, IFN gamma transforming growth factor (TGF) beta (ELISA/intracellular 
cytokine staining) 
o For monocytes:  CD40L- and Staphylococcus aureus Cowan (SAC)-stimulated 
secretion/production of IL-12 p70, and LP S-stimulated secretion of IL-10 
(ELISA/intracellular cytokine staining) 
Patients who do not fulfill the criteria on screening w ill be discharged back to the care of referring 
physicians. 
5.2 S TUDY POINT 2:  TREATMENT #[ADDRESS_909920] the following: 
x History and physical, including review of medications, weight measurement, assessment of 
number and consistency of stools per day, assessment for any current infection and 
documentation of any infections since the last visit. 
x Pregnancy test (for females of childbearing potential). 
x Vital signs will be taken prior to administration of study agent. 
x Administration of study agent by [CONTACT_673397]: A dose of 
ustekinumab [ADDRESS_909921] will be observed for 1 hour following ad ministration of study agent, with another set 
of vital signs taken at the end of the observation period. 
5.3 S TUDY POINT 3:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #[ADDRESS_909922]. 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 28 
5.4 S TUDY POINT 4:  PHONE CALL - 2 WEEKS AFTER TREATMENT #1 (+/-  3 DAYS ) 
 
Surveillance phone call with the subject to monitor for adverse effects or signs of infection and to 
review concomitant medications and compliance with pregnancy avoidance measures as applicable to the subject. 
5.5 S
TUDY POINT 5:  TREATMENT #2 VISIT - WEEK 8 (+/-  4 DAYS ) 
At the Week [ADDRESS_909923] the following: 
x History and physical, including medication review, weight measurement, assessment of 
number and consistency of stools per day, assessment for any current infection and 
documentation of any infections since the last visit. 
x Blood tests: 
o CBC with differential 
o Chemistry 
o ESR and CRP  
o PT/PTT/INR 
o Quantitative Immunoglobulins 
x Urine and stool tests: 
o Urinalysis 
o Pregnancy test (for females of childbearing potential) 
o Stool sample for GI pathogens  
o Stool sample for fecal calprotectin level 
o Stool sample for microbiota research studies 
x Vital signs will be taken prior to administration of study agent. 
x Administration of study agent by [CONTACT_673397]: A dose of 
ustekinumab [ADDRESS_909924] will be observed for 1 hour following ad ministration of study agent, with another set 
of vital signs taken at the end of the observation period.  
5.6 S TUDY POINT 6:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #[ADDRESS_909925]. 
5.7 S TUDY POINT 7:  PHONE CALL - 2 WEEKS AFTER TREATMENT #2 (+/-  3 DAYS ) 
 
Surveillance phone call with the subject to monitor for adverse effects or signs of infection and to 
review concomitant medications and complian ce with pregnancy avoidance measures as 
applicable to the subject. 
5.8 S TUDY POINT 8:  TREATMENT #3 VISIT - WEEK 16 (+/-  4 DAYS ) 
At the Week [ADDRESS_909926] the following: 
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909927] visit. 
x Blood tests: 
o CBC with differential 
o Chemistry  
o ESR and CRP  
o PT/PTT/INR  
o Quantitative Immunoglobulins 
x Urine and stool tests: 
o Urinalysis 
o Pregnancy test (for females of childbearing potential) 
o Stool sample for GI pathogens  
o Stool sample for fecal calprotectin level  
o Stool sample for microbiota research studies 
x Vital signs will be taken prior to administration of study agent. 
x Administration of study agent by [CONTACT_673397]: A dose of 
ustekinumab [ADDRESS_909928] will be observed for 1 hour following ad ministration of study agent, with another set 
of vital signs taken at the end of the observation period. 
5.9 S TUDY POINT 9:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #[ADDRESS_909929]. 
5.10 S TUDY POINT 10:  PHONE CALL - 2 WEEKS AFTER TREATMENT #3 (+/-  3 DAYS ) 
 
Surveillance phone call with the subject to monitor for adverse effects or signs of infection and to review concomitant medications and compliance with pregnancy avoidance measures as applicable to the subject. 
5.11 S
TUDY POINT 11:  TREATMENT #4 VISIT - WEEK 24 (+/-  4 DAYS ) 
At the Week [ADDRESS_909930] the following: 
x History and physical, including medication review, weight measurement, assessment of 
number and consistency of stools per day, assessment for any current infection and 
documentation of any infecti ons since the last visit. 
x Blood tests: 
o CBC with differential 
o Chemistry  
o ESR and CRP  
o PT/PTT/INR 
o Quantitative Immunoglobulins 
x Urine and stool tests: 
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909931] (for females of childbearing potential) 
o Stool sample for GI pathogens  
o Stool sample for fecal calprotectin level 
o Stool sample for microbiota research studies 
o Stool collections for measurement of fat malabsorption (48 hour fecal fat) and protein 
loss (24 hour A1AT clearance) 
x D-xylose absorption study 
x Vital signs will be taken prior to administration of study agent. 
x Administration of study agent by [CONTACT_673397]: A dose of 
ustekinumab [ADDRESS_909932] will be observed for 1 hour following ad ministration of study agent, with another set 
of vital signs taken at the end of the observation period.  
5.12 S TUDY POINT 12:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #[ADDRESS_909933]. 
5.13 S TUDY POINT 13:  PHONE CALL - 2 WEEKS AFTER TREATMENT #4 (+/-  3 DAYS ) 
 
Surveillance phone call with the subject to monitor for adverse effects or signs of infection and to 
review concomitant medications and compliance with pregnancy avoidance measures as applicable to the subject. 
5.14 S
TUDY POINT 14:  TREATMENT #5 VISIT - WEEK 32 (+/-  4 DAYS ) 
At the Week [ADDRESS_909934] the following: 
x History and physical, including medication review, weight measurement, assessment of 
number and consistency of stools per day, assessment for any current infection and 
documentation of any infections since the last visit. 
x Blood tests: 
o CBC with differential 
o Chemistry 
o ESR and CRP  
o PT/PTT/INR  
o Quantitative Immunoglobulins 
x Urine and stool tests: 
o Urinalysis 
o Pregnancy test (for females of childbearing potential) 
o Stool sample for GI pathogens  
o Stool sample for fecal calprotectin level 
o Stool sample for microbiota research studies 
x Vital signs will be taken prior to administration of study agent. 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 31 
x Administration of study agent by [CONTACT_673397]: A dose of 
ustekinumab [ADDRESS_909935] will be observed for 1 hour following ad ministration of study agent, with another set 
of vital signs taken at the end of the observation period. 
5.15   S TUDY POINT 15:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #[ADDRESS_909936]. 
5.16 S
TUDY POINT 16:  PHONE CALL - 2 WEEKS AFTER TREATMENT #5 (+/-  3 DAYS ) 
 
Surveillance phone call with the subject to monitor for adverse effects or signs of infection and to 
review concomitant medications and compliance with pregnancy avoidance measures as applicable to the subject. 
5.17 S
TUDY POINT 17:  TREATMENT #6 VISIT - WEEK 40 (+/-  4 DAYS ) 
At the Week [ADDRESS_909937] the following: 
x History and physical, including medication review, weight measurement, assessment of 
number and consistency of stools per day, assessment for any current infection and 
documentation of any infecti ons since the last visit. 
x Blood tests: 
o CBC with differential 
o Chemistry 
o ESR and CRP  
o PT/PTT/INR  
o Quantitative Immunoglobulins 
x Urine and stool tests: 
o Urinalysis 
o Pregnancy test (for females of childbearing potential) 
o Stool sample for GI pathogens  
o Stool sample for fecal calprotectin level 
o Stool sample for microbiota research studies 
x Vital signs will be taken prior to administration of study agent. 
x Administration of study agent by [CONTACT_673397]: A dose of 
ustekinumab [ADDRESS_909938] will be observed for 1 hour following ad ministration of study agent, with another set 
of vital signs taken at the end of the observation period. 
5.18   S TUDY POINT 18:  PHONE CALL - WITHIN 3 DAYS OF TREATMENT #[ADDRESS_909939].  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 32 
5.19 S TUDY POINT 19:  PHONE CALL - 2 WEEKS AFTER TREATMENT #6 (+/-  3 DAYS ) 
 
Surveillance phone call with the subject to monitor for adverse effects or signs of infection and to 
review concomitant medications and compliance with pregnancy avoidance measures as applicable to the subject.
 
5.20 S TUDY POINT 20:  ENDPOINT VISIT - WEEK 48 (+/-  5 DAYS ) 
At the Week 48 Endpoint Visit, the patient may be admitted as an inpatient at the NIH Clinical 
Center for approximately 5-7 days for the following: 
x History and physical, including medication review, weight measurement, assessment of 
number and consistency of stools per day, assessment for any current infection and 
documentation of any infections since the last visit. 
x Blood tests: 
o CBC with differential 
o Chemistry (acute care panel, mineral panel,  hepatic panel, creatine kinase, lactate 
dehydrogenase, total protein, uric acid) 
o ESR and CRP  
o PT/PTT/INR 
o Quantitative immunoglobulins 
x Urine and stool tests: 
o Urinalysis 
o Pregnancy test (for females of childbearing potential) 
o Stool collections for measurement of fat mala bsorption (48 hour fecal fat) and protein 
loss (24 hour A1AT clearance).  
o Stool sample for GI pathogens  
o Stool sample for fecal calprotectin level 
o Stool sample for microbiota research studies 
x EGD and/or colonoscopy to evaluate the extent and severity of inflammation via photography, 
biopsy for descriptive histopathology (4 to 6 biopsies) and histologic scoring (modified 
d’Haens score), and for collection of LPMCs (up to 30 biopsies).  Biopsies from the gut may also be used to study gut microbiota.  Th e EGD and/or colonoscopy performed during the pre-
treatment phase will be repeated at this visit.  
x D-xylose absorption test. 
x Blood collection for the additional testing of th e following (some or all) PBMCs and LPMCs 
from endoscopic biopsies: 
o For CD4+ cells:  Stimulated secretion/production of IL-4, IL-5, IL-6, IL-10, IL-13, 
IL-17, IFN gamma TGF beta (ELISA/intracellular cytokine staining) 
o For monocytes:  CD40L- and SAC-stimul ated secretion/producti on of IL-12 p70, and 
LPS-stimulated secretion of IL-10 (E LISA/intracellular cytokine staining) 
x Assessment of mRNA production in suspected inflammatory pathways by [CONTACT_673396] (research testing on GI biopsies) 
x Global gene expression microarray (research testing on GI biopsies) 
 
5.21 U NSCHEDULED VISITS  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 33 
 
Patients may be asked to return for an unsche duled visit to evaluate any adverse event or 
unanticipated problem that may be related to participation in the study.  
6.0 ANALYSIS OF THE STUDY 
6.1 S AMPLE SIZE JUSTIFICATION   
The sample size is justified as follows: Previous  studies have shown that ustekinumab is well 
tolerated. It is anticipated that the rate of SAE will  be low. The chance of experiencing any serious 
adverse event is believed to be less than 5%. Table [ADDRESS_909940] 
one SAE for several assumed true event rates. Wi th the planned sample size (10), the probability 
of observing at least one subject with a SAE is 40% if the rate of SAE is 5%.  
Table 1: The probability of at least one subject for various SAE rate with the 
planned sample size (10) 
 
True SAE rate  1% 5% 10% 
Probability of observing at 
least 1 SAE  10% 40% 65% 
 
Because of the small sample size of this study, th e exact confidence interval associated with the 
estimated SAE rate will be reported by [CONTACT_673398], where the width of the 
confidence interval indicates the degree of uncer tainty about the estimated adverse event rate. 
Table [ADDRESS_909941] 95% confidence intervals (CIs) for 
various SAE rates with a sample size of 10. For example the 95% CI for the true SAE rate is 
(0.0025, 0.45) with a width of 0.45 if 1 of 10 subjects experience SAE during the study period.   
Table 2:  The binomial exact 95% for various AE rates with the planned sample size (10) 
 
Number of 
patients with SAE  0 1 2 3 4 5 
Observed SAE 
rate 0% 10% 20% 30% 40% 50% 
95% CI for true 
SAE rate  (0%, 
31%) (0.25%, 
45%) (2.5%, 
56%) (6.7%, 
65%) (12%, 
74%) (18.7%, 
81.3%)  
 
6.2 S TATISTICAL ANALYSIS PLAN 
6.2.1 General Considerations 
Statistical tests will be two-sided and carried out at the 0.05 level unless otherwise indicated. 
Continuous data will be summarized using th e number of observations available: mean, standard 
deviation, minimum, median, and maximum. Categori cal data will be summarized using counts 
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909942] 1 associated SAE will be ca lculated, along with the 95% exact CIs. Statistical analysis for the 
primary safety endpoint will be performed on sa fety population, which consists of all subjects who 
received a dose. For interim safety reviews, this wi ll be limited to data entered into the electronic 
database up to the cut-off date. To further describe  the AE experience, rates will be presented for 
individual types of SAEs as well as for lower grade AEs. 
6.2.3 Efficacy Analyses  
As a secondary analysis, the analysis of efficacy endpoints will be performed on the intention-to-
treat population, which will consis t of all enrolled subjects comprising CVID and selective IgG 
subclass deficiency patients (r egardless of the cumulative dose , and regardless of whether they 
receive treatment or not). Subjects who withdraw voluntarily or by [CONTACT_673399]. The proporti on of subjects with a clinical response will be 
reported, along with the 95% exact CIs.  Response w ill be defined as <1% decrease in weight or a 
decrease in the number of stools at the Week 8, Week 16, Week 24, Week 32 and Week 40 visit 
compared to Day 0 baseline values. Based on initial three subjects’  data, the observed standard 
error for the weight gain at months [ADDRESS_909943] 6.2 
pounds. With 10 subjects, the power of detecting  6.2 pounds or more weight gain at months 6 is 
80% (with type I error of 0.05). The same analysis will be performed for other binary secondary 
efficacy endpoints. The comparison between chan ges in responders and non-responders in terms 
of change in immunologic laboratory parameter s will be grouped for all enrolled patient 
populations (e.g., stimulated proinflammatory cytokine lev els) from baseline will be performed by 
[CONTACT_673400]-sum test at the Week [ADDRESS_909944] of Good Clinical Practice (GCP) principles of clinical 
research and the regulatory requirements for th e protection of human subjects. All investigators 
collaborating in this study have met the traini ng requirements of the Office of Human Subjects 
Research. Copi[INVESTIGATOR_673344] (Principal Investigator [PI] and Associate Investigators [AI]) will be kept updated 
and on file. 
7.[ADDRESS_909945] (I RB) will be notified. 
7.[ADDRESS_909946] OF THE STUDY  
This study will be conducted in accordance w ith all applicable laws and regulations, policies of 
the National Institute of Allergy and Infectious Di seases (NIAID) IRB as well as the policies of 
NIAID and NIH. The PI [INVESTIGATOR_673345], except where necessary to eliminate an 
immediate hazard(s) to the study participants. The PI [INVESTIGATOR_673346]. 
7.[ADDRESS_909947] moderate to severe  intestinal symptoms 
reflecting malabsorption. Recruitment will large ly be from within the NIH population of CVID 
patients (>300 patients) as well as continued referral from the Office  of Patient Recruitment.  Print 
advertising in local newspape rs, public access cable public servi ce announcements, and print and 
internet notices through the NIH recruitment mecha nism will be used. In addition, letters to 
clinicians who provide care for primary immunodeficien cy diseases may be sent in order to solicit 
referrals. Any advertising and recruitment mater ials will be submitted to the NIAID IRB for 
approval prior to distribution.  
7.5 J USTIFICATION OF THE EXCLUSION OF WOMEN AND CHILDREN (SPECIAL POPULATIONS ) 
7.5.1 Exclusion of Children 
Because there are insufficient data regarding dosing or adverse events in this specific patient 
population to judge the potential risk in children, children are excluded from this study.  
7.5.2 Exclusion of Pregnancy  
Pregnant women are excluded from this study because the effects of the study agent on the 
developi[INVESTIGATOR_19241].  
7.5.3 Breastfeeding 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 36 
Because there is an unknown but potential risk for a dverse effects in nursing infants secondary to 
treatment of the mother with the study agent, breastfeeding women are excluded from this study. 
8.0 POTENTIAL RISKS AND BENEFITS 
8.1         POTENTIAL BENEFITS  
Patients with CVID enteropathy, exhibit villous  atrophy of the small bowel mucosa and a complex 
of associated symptoms including chronic diarrh ea, malabsorption marked by [CONTACT_673401], and protein-losing enteropathy leading to loss of albumin and other proteins into the fecal 
stream. These symptoms can lead to severe weight loss, hypoalbuminemia predisposing to edema, and the need for nutrient supplementation ( Mannon et al 2006 ). Additionally, many patients 
develop non-infectious gastrointestinal manifestati ons that can be disabling or fatal. Currently 
there is no standard therapy for the associated ga strointestinal disease outside of empi[INVESTIGATOR_673335], anti-diarrheal agents , and non-specific anti-inflammatory agents. The 
potential benefit of this study will be the generali zable knowledge about this disease and treatment 
options.   
8.2 P
OTENTIAL HAZARDS AND DISCOMFORTS   
8.2.1 Risks of Ustekinumab (Stelara®) 
Further detailed information on adverse events can be found in the Stelara® Data Sheet ( Appendix 
B) and the Stelara® Prescribing Information ( Appendix C ). 
Stelara® is classified in Pregnancy Category B ba sed on animal studies.  There have been no 
adequate and well controlled studies in pregnan t women, so risks to pregnant mothers and the 
developi[INVESTIGATOR_15165].  Stelara is excreted in breast milk, and the extent to which it may 
be absorbed through breastmilk is unknown.  Due to these risks, women cannot participate in this study if they are pregnant or breastfeeding.  Su bjects must either meet exclusion criteria for 
contraception as described in Section 4.1, Inclus ion Criteria, or must agree to consistently use 
agreed upon contraceptive methods to prevent pr egnancy during through the Week [ADDRESS_909948] exposure to Stelara
® in [ADDRESS_909949] 18 months.  
The following serious adverse reactions were reported:  
x Serious Infections 
x Malignancies  
The most common adverse reactions (>10%) in controlled and uncont rolled portions of the 
psoriasis clinical studies with Stelara® were nasopharyngitis and upper respi[INVESTIGATOR_1092]. 
Most were considered to be mild and did not necessitate drug discontinuation.  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 37 
The following table provides a summary of Adverse Drug Reactions from psoriasis clinical 
studies. The adverse drug reactions are ranked by [CONTACT_35043], using the following convention:  
x Very common (>1/10) 
x Common (frequent) (>1/100, <1/10)  
x Uncommon (infrequent) (>1/1,000, <1/100) 
x Rare (>1/10,000, <1/1,000) 
 
Table 3:  Summary of Adverse Drug Reactions 
 
 
 
Infections  
In controlled studies of psoriasis patients, the ra tes of infection or serious infection were similar 
between Stelara®-treated patients and those treated with  placebo. In the placebo-controlled period 
of clinical studies of psoriasis patients, the rate  of infection was 1.39 per patient-year of follow-up 
in Stelara®-treated patients, and 1.21 per patient-year  of follow-up in placebo-treated patients. 
Serious infections occurred in 0.01 pe r patient-year of follow-up in Stelara®-treated patients (5 
serious infections in 407 patient-years of fo llow-up) and 0.02 per patient-year of follow-up in 
placebo-treated patients (3 serious infe ctions in 177 patient-years of follow-up).  
In the controlled and non-controlle d portions of psoriasis clinical studies, the rate of infection was 
1.24 per patient-year of follow-up in Stelara®-treated patients. The incidence of serious infections 
was 0.01 per patient-year of follow-up in Stelara®-treated patients (24 serious infections in 2251 
patient-years of follow-up) and included cellulitis, diverticulitis, osteomyelitis, viral infections, 
gastroenteritis, pneumonia, and urinary tract infections.  
Among 3117 patients treated in 4 psoriasis clinical trials of Stelara® (median follow up of 3.2 
years) representing 8998 patient-years of exposure ([ADDRESS_909950] 5 years), the rates of infection or serious 
infection were similar to those described above. In clinical studies, patients with latent tuberculosis 
who were concurrently treated with isoniazid did not develop tuberculosis. 

Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 38 
In psoriasis patients, the infection rate did not in crease significantly, however as patients with 
CVID are already pre-disposed to certain types of infections, treatment with ustekinumab could 
further weaken the immune system, potentially placing the patient at a higher risk of infection.   
Malignancies  
In the controlled period of the 3 placebo-controlled  psoriasis clinical studies, the incidence of 
malignancies excluding non-melanoma skin cance r was 0.25 per 100 patient-years of follow-up 
for Stelara®-treated patients (1 patien t in 406 patient-years of follo w-up) compared with 0.57 per 
100 patient-years of follow-up for placebo-treated patients (1 patient in 177 patient-years of 
follow-up).  
The incidence of non-melanoma skin cancer was 0.74 per 100 patient-years of follow-up for 
Stelara® -treated patients (3 patients in 406 patien t-years of follow-up) compared with 1.13 per 
100 patient-years of follow-up for placebo-treated patients (2 patients in 176 patient-years of 
follow-up).  
Among 3117 patients treated in 4 psoriasis clin ical trials (median follow up of 3.2 years) of 
Stelara® ([ADDRESS_909951] 5 years), malignancies excluding non-melanoma skin cancers were reported in 54 
patients in 8980 patient-years of follow-up (i ncidence of 0.60 per 100 patient-years of follow-up 
for Stelara®-treated patients). This rate of malignancies reported in Stelara®-treated patients was 
comparable to the rate expected in the gene ral population (standardized incidence ratio = 0.98 
[95% confidence interval: 0.74, 1.29], adjusted for age, gender and race). The most frequently 
observed malignancies, other than non-mela noma skin cancer, were prostate, melanoma , 
colorectal and breast. The incide nce of non-melanoma skin cancer was 0.52 per 100 patient-years 
of follow-up for Stelara®-treated patients (47 patients in 8965 patient-years of follow-up).  
Hypersensitivity Reactions  
In clinical studies of Stelara®, rash and urticaria have each been observed in <2% of patients. 
Immunogenicity  
Approximately 5% of patients treated with Stelara® developed antibodies to ustekinumab, which 
were generally low-titre. No apparent correl ation of antibody developm ent to injection site 
reactions was seen. The majority of patients who were positive for antibodies to ustekinumab had 
neutralizing antibodies. Patients positive for antibodies to Stelara® tended to have lower efficacy, 
however, antibody positivity does not preclude a clinical response.  
Adverse Events  
The following adverse events have been reported in patients treated with Stelara®. A causal 
relationship to Stelara® is uncertain.  
In psoriasis clinical trials of Stelara®, serious cardiovascular events, including cardiovascular 
death, myocardial infarction, and stroke, were rep orted in 0.3% of patients who received Stelara® 
compared with 0% of patients treated with placebo, during the placebo-controlled period. 
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909952] higher rates of 
cardiovascular risk factors and cardiovascular events. Rates of my ocardial infarction and stroke 
reported in Stelara®-treated patients were comparable to ra tes expected in the general population.  
Adverse events of depression were report ed in some patients who received Stelara® in psoriasis 
clinical trials, including rare events of suicidality. Individuals with psoriasis have higher rates of 
depression, and it is not known if Stelara® may have contributed to these events since Stelara® also 
resulted in improvements of the Hospi[INVESTIGATOR_5620].  
Crohn’s Disease Clinical Studies Experience  
Of note, there was no significant increase in rate of serious infections or any other serious adverse 
events in the ustekinumab treatment versus p lacebo groups in either of the 2 published phase II 
studies in CD ( Sandborn et al, 2008, Sandborn et al 2012 ).   
8.2.2 Risks and Discomforts of Phlebotomy   
Blood draws may cause pain and bruising and, rare ly, infection. Sometimes drawing blood causes 
people to feel lightheaded or even faint.  The amount of blood drawn will be within the limits 
allowed for adult subjects by [CONTACT_4517] (Medical Administrative Policy 95-9: Guidelines for Limits of Blood Drawn for Rese arch Purposes in the Clinical Center:   http://cc-
internal.cc.nih.gov/policies/PDF/M95-9.pdf  
8.2.3 Risks and Discomforts of EGD and/or Colonoscopy with Biopsies  
Diagnostic esophagogastroduodenoscopy (EGD) and colonoscopy are generally safe and well 
tolerated, even in high-risk subject groups (Cappell, 1996 and Terheggen, 2008) . The majority of 
morbidity and mortality from these diagnos tic procedures is related to cardiopulmonary 
complications of conscious sedation (aspi[INVESTIGATOR_673347], arrhythmia, hypoxemia) (Hart 
and Classen, 1990)  with rates of attributable advers e outcomes and fatality of 0.54% and 0.03%, 
respectively.  
As a general practice, this risk is minimized by [CONTACT_247756], blood pressure, and oxygen 
saturation throughout the procedure. The proce dure-related complications of EGD include 
perforation (0.8-4/10,000 procedures), bleeding (2-6/10,000 procedures), and bacteremia (about 4% incidence rate usually associated with ther apeutic maneuvers such as dilation, mucosal 
injection, or electrocautery) that ra rely has attributable sequelae ( Froehlich et al., 1999 ). The 
overall estimates of total morbidity and m ortality from diagnostic EGD are 14-20/10,000 
procedures and 0-7/10,000 respectively. At the Clinical Center, patients undergoing EGD are 
informed that the cardiopulmonary complication rate is 6/10,000 procedures, esophageal perforation is 3/10,000, and death 7/10,000.  
For colonoscopy the reported mortality rates are 2-6 deaths/10,000 colonoscopi[INVESTIGATOR_014]
 (Froehlich et al., 
1999); subjects at the Clinical Center are informe d that the complication rates with colonoscopy 
are 2-4 perforations/1,000 colonoscopi[INVESTIGATOR_014], 10 perforations/1,000 colonoscopic polypectomies, 25 
clinically significant bleeding epi[INVESTIGATOR_1841]/1,000 colonoscopic polypectomies, 1 death/10,000 
colonoscopi[INVESTIGATOR_014], and 2 deaths/1,[ADDRESS_909953] exclusively associated with excess tension due to scope movement, 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 40 
inadvertent passage of an instrument (e.g., biops y forceps) through the wall, or over-insufflation 
of a segment of bowel and is reported to range from 0.03% to 0.65% for diagnostic colonoscopy 
and 0.073% to 2.14% in therapeutic procedure (Damore et al., 1996) .  While colonoscopy in the 
setting of active colitis may carry an increased risk of perforation due to these mechanisms, there 
are no data available on this risk in populations of subjects with inflammatory bowel disease (Irvine  and Hunt, 1997) . On the other hand, it is generally accepted that endoscopic biopsy-related 
perforation of the colon is a rare event overall, th ough it has been recognized to occur anecdotally 
in particular settings including in an area of atrophic mucosa over th inned bowel musculature 
(Eckardt et al., 1997)  and in the ceca of elderly subjects w ith bowel walls thinned by [CONTACT_673402] (likely ischemia-related)  mucosal ulceration and inflammation (Foliente et al., 1996) .   
Similarly, clinically significant bleeding afte r colonoscopic mucosal biopsy is “exceedingly rare” 
(Raijman et al., 1992)  with no epi[INVESTIGATOR_673348] (requiring post-procedural 
evaluation or treatment) afte r cold biopsy in 2 series (Macrae et al., 1983; Shiffman et al., 1994)  
and an estimate of minor bleeding (asymptomatic, self -limited, spotting on toilet paper or coloring 
toilet water) of 2.2% ( Shiffman et al., 1994 ). There was no data found relating specifically to the 
risk of bleeding to the number of biopsies taken per procedure.  Only one published report of a single epi[INVESTIGATOR_673349] a si ngle cold biopsy of the cecum could be found 
(Raijman et al., 1992 ).   
However, research endoscopi[INVESTIGATOR_673350]. In a recent large scale study of 253 research endoscopi[INVESTIGATOR_014] (169 colonoscopi[INVESTIGATOR_014], 64 
sigmoidoscopi[INVESTIGATOR_014], and 24 upper endoscopi[INVESTIGATOR_014]) performe d at the NIH Clinical Center, where a total 
of 9661 biopsy specimens were taken for research and histopathology purposes, no major complications occurred. There were 5 epi[INVESTIGATOR_673351], 4 epi[INVESTIGATOR_673352], and 4 
epi[INVESTIGATOR_673353] 253 proce dures, all of which were self-limiting.  There 
was no statistical significance between the num ber of biopsies, type of procedure, location of 
biopsies and the risk of complications ( Yao et al, 2009 ). 
Because of the large number of biopsies planned pe r endoscopy, the subjects will be informed of 
the potential for an increased risk of bleeding an d perforation. In order to prevent complications 
and minimize their impact, study investigators will  avoid biopsies within ulcerated regions (where 
relative thinning of the gut wall may be pres ent), avoid over-insufflation during biopsies, and 
provide post procedure instructions for subjects to recognize early warning signs of significant 
complications (abdominal pain, fever, persiste nt hematochezia) while providing mechanisms for 
early evaluation and treatment at the Clinical Center (being available 24 hours a day by [CONTACT_3264], 
having emergency radiology, surgical consultation, and endoscopy available). 
8.2.[ADDRESS_909954] result could potentially result in 
discrimination, stigmatization or difficulties with insurability. The attendant responsibilities of reporting, notification of partners, and limits of confidentiality will be fully discussed. 
8.2.5 Risks and Discomforts of Tests of Gut Function 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 41 
These tests require no instrumentation while blood a nd stool are collected. Substances are taken 
orally (e.g., D-xylose) and have no significant toxi cities outside of a potential for transient nausea. 
8.2.[ADDRESS_909955] is a total of 0.2 to 1.6 rem 
(which is well below the guideline of [ADDRESS_909956]'s involvement in the research. Discussions about the research will 
provide essential information about the study and include: purpose, duration, experimental 
procedures, alternatives, risks and benefits. Subjects  will be given the opportunity to ask questions 
and have them answered.  
The subjects will sign the informed consent document prior to undergoing any research 
procedures. The subjects may withdraw consent at any time throughout the course of the trial. A 
copy of the informed consent document will be given to the subjects for their records. The 
researcher will document the signing of the cons ent form in the subject’s medical record. The 
rights and welfare of the subjects will be protected by [CONTACT_21223].  
8.[ADDRESS_909957], except as necessary for monitoring by [CONTACT_3433] e IRB, FDA, NIAID, Office for Human Research 
Protections (OHRP) , or sponsor’s designee.  
9.[ADDRESS_909958], information rega rding adverse events will be elicited by 
[CONTACT_4524]:  
x Immediately documented in the subject’s medical record/source document,  
x Recorded in the electronic database, and 
x Reported as outlined below (e.g., IND Sponsor, IRB, and FDA). 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 42 
9.2 D EFINITIONS  
Adverse Event (AE) 
An adverse event is any untoward or unfavorable med ical occurrence in a human subject, including 
any abnormal sign (e.g., abnormal physical exam  or laboratory finding), symptom, or disease, 
temporally associated with the subject’s participat ion in the research, whether or not considered 
related to the research.  
Adverse Reaction (AR) 
An adverse event that is caused by [CONTACT_4523] (drug or biologic). 
 
Suspected Adverse Reaction (SAR) 
An adverse event for which there is a reasonable po ssibility that the investigational agent caused 
the adverse event. ‘Reasonable possibility’ mean s that there is evidence to suggest a causal 
relationship between the drug and the adverse event.  A suspected adverse reaction implies a lesser 
degree of certainty about causality than adverse re action which implies a high degree of certainty. 
 
Serious Adverse Event (SAE) 
A Serious Adverse Event is an AE that results in one or more of the following outcomes: 
x Death 
x A life threatening (i.e., an immediate threat to life) event 
x An inpatient hospi[INVESTIGATOR_1324] 
x A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
x A congenital anomaly/birth defect 
x A medically important event* 
 
* Medical and scientific judgment should be exerci sed in deciding whether expedited reporting 
is appropriate in other situations, such as important medical events that may not be immediately life threatening or result in death or hospi[INVESTIGATOR_673354].  
 
Unexpected Adverse Event 
An AE is unexpected if it is not listed in the Investigator’s Brochure  or Package Insert (for 
marketed products) or is not listed at the specificity or severity that has been observed.  It is the 
responsibility of the IND Sponsor to make this determination.  
Serious and Unexpected Suspected Adverse Reaction (S[LOCATION_003]R) 
A S[LOCATION_003]R is a Suspected Adverse Reaction that is both Serious and Unexpected.   
 
Unanticipated Problem (UP) 
An Unanticipated Problem is any event, incident, experience, or outcome that is: 
1.  Unexpected in terms of nature, se verity, or frequency in relation to 
a. The research risks that are described in the IRB-approved research protocol and informed 
consent document; Investigator’s Brochure or other study documents; and  
b. The characteristics of the subject population being studied; and 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 43 
2. Possibly, probably, or definitely related to participation in the research; and 
3. Places subjects or others at a greater risk of harm (including physical, psychological, 
economic, or social harm) than was previously known or recognized. (Per the IND Sponsor, an AE with a serious outcome will  be considered increased risk.) 
 
Serious Unanticipated Problem (UP): A UP that meets the definition of a Serious Adverse Event 
or compromises the safety, welfare or rights of subjects or others. 
 
Unanticipated Problem that is n ot an Adverse Event (UPnonAE) 
Unanticipated problem that is not an Adverse Event (UPnonAE): An unanticipated problem that 
does not fit the definition of an adverse event, but which may, in the opi[INVESTIGATOR_871], 
involve risk to the subject, affect others in the re search study, or significantly impact the integrity 
of research data.  Such events would be consider ed a non-serious UP. For example, we will report 
occurrences of breaches of confi dentiality, accidental destruction of study records, or unaccounted-
for study drug.  Protocol Deviation:  Any change, divergence, or departure from the IRB approved study 
procedures in a research protocol. Protocol deviati ons are designated as serious or non-serious and 
further characterized as: 
1. Those that occur because a member of the research team deviates from the protocol 
2. Those that are identified before they occur, but cannot be prevented 
3. Those that are discovered after they occur. 
 Serious Protocol Deviation:  A deviation that meets the definition of a Serious Adverse Event or 
compromises the safety, welfare or rights of subjects or others. 
 
Non-compliance: The failure to comply with applic able NIH Human Research Protection 
Program (HRPP) policies, IRB requirements, or regulatory requirements for the protection of human subjects. Non-compliance is further characterized as: 
1. Serious: Non-compliance that: 
a. Increases risks, or causes harm, to participants 
b. Decreases potential benefits to participants 
c. Compromises the integrity of the NIH-HRPP 
d. Invalidates the study data. 
2. Continuing: Non-compliance that is recurring 
3. Minor: Non-compliance that, is neither serious nor continuing.   
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 44 
9.3 I NVESTIGATOR ASSESSMENT OF ADVERSE EVENTS  
All AEs occurring from the time the informed consent is signed through the day prior to dosing 
(through day -1) will EITHER be recorded and reported as a baseline condition (if unrelated to 
study procedures), OR will be reported as required for AEs or SAEs (if possibly, probably or definitely related to study procedures.)   
From the time the informed consent is signed through the 48 week visit, all AEs will be 
documented, recorded, and reported as required for AEs and SAEs.   
After the 48 week visit, SAEs (including AEs re quiring hospi[INVESTIGATOR_059]) will be reported in an 
expedited manner (i.e., as required for SAEs) if  possibly, probably, or definitely related to the 
study drug, and will otherwise be reported to Sponsor and IRB annually.  Therefore, after week [ADDRESS_909959]-dosing, in-patient admission to the NIH or other hospi[INVESTIGATOR_673355], probably or definitely relat ed to the disease process under study AND that 
is unlikely or definitely NOT related to study drug, will not be reported in expedited manner.   
Inpatient hospi[INVESTIGATOR_673356], i.e., for the purpose of protocol 
participation alone, will not be considered an  AE or SAE.  Emergency room and day or night 
survey visits are not considered serious until one of the above criteria is met.  Any elective 
hospi[INVESTIGATOR_272] a baseline  condition (i.e. a condition that is documented as to its precise nature 
and severity) that has been documented to exist at  the time of baseline evaluation, AND that has 
not worsened, does not constitute a serious adverse event.  
Recurrence of an infection that was documented as having been pres ent within 30 days of baseline, 
will not be recorded as an AE unless it: 
x is a new diagnosis based on greater specificity, and/or  
x has worsened as to severity, nature, or frequency 
Infections typi[INVESTIGATOR_673357] y include infections such as: 1) sinopulmonary 
infections secondary to streptococcus pneum onia, hemophilus influenzae, or mycoplasma; 2) 
gastrointestinal infections secondary to giard ia, campylobacter, or salmonella.  Many CVID 
patients also have abnormal lab va lues at baseline, so any abnormal lab values reported while on 
this study will only be assessed as an AE if it is a new diagnosis and/or worsening, requiring clinical treatment. 
If a diagnosis is clinically evident (or subsequently determined), the diagnosis rather than the 
individual signs and symptoms or lab abnormalities will be recorded as the AE. 
 
A laboratory abnormality should be reported as an a dverse event if it requires an intervention.  
Interventions include, but are not limited to, di scontinuation of treatment, dose reduction/delay, 
additional assessments, or concomitant treatment.   In addition, any medically important laboratory 
abnormality may be reported as an adverse event at the discretion of the investigator.  This could 
include a laboratory result for which there is no intervention but the abnormal value suggests a 
disease or organ toxicity.  
 
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909960] to Seriousness  (criteria listed above), Severity 
(intensity or grade), and Causality  (relationship to study agent and relationship to research) 
according to the following guidelines.  
9.3.[ADDRESS_909961] current version of the Common Terminol ogy Criteria for Adverse Events (CTCAE) will 
be used for grading adverse events from any of the research procedures: 
http://ctep.cancer.gov/protocolDevelopment/elect ronic_applications/ctc.htm will be used  
Severity grading for clinical events not found in th e Toxicity Table will be graded according to the 
following grading scale: 
x Grade 1 (Mild):  Events causing no or minimal interference with usual social and functional 
activities. 
x Grade 2 (Moderate):  Events causing greater th an minimal interference with usual social and 
functional activities. 
x Grade 3 (Severe):  Events causing inability to  perform usual social and functional activities. 
x Grade 4 (Potentially Life-Threatening)*:  Events  causing inability to perform basic self-care 
functions OR medical or operative intervention indicated to prevent permanent impairment, 
persistent disability, or death. 
x Grade 5 (Death) 
* Note:   A severity assessment of “potentially life -threatening” is not necessarily the same as  life-
threatening when used as an "SAE" criterion. The latter means that the event is an immediate 
threat to life as opposed to a potential threat to life. 
9.3.2 Causality    
Causality (likelihood that the event is related to the study agent) will be assessed 
considering the factors listed under the following categories:  
 
Definitely Related    
x Reasonable temporal relationship 
x Follows a known response pattern 
x Clear evidence to suggest a causal relationship 
x There is no alternative etiology 
 
Probably Related  
x Reasonable temporal relationship 
x Follows a suspected response pattern (based on similar agents) 
x No evidence of a more likely alternative etiology 
 
Possibly Related  
x Reasonable temporal relationship 
x Little evidence for a more likely alternative etiology 
 
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909962] a temporal relationship          
OR 
x Definitely due to an alternative etiology 
 
Note: Other factors (e.g., dechallenge, rechalle nge) should also be considered for each 
causality category when appropriate. Caus ality assessment is based on available 
information at the time of the assessment of the AE. The investigator may revise the 
causality assessment as additional information becomes available. 
9.4 I NVESTIGATOR REPORTING RESPONSIBILITIES TO THE SPONSOR  
9.4.1 Adverse Events 
Line listings, frequency tables, and other summary AE data will be submitted to the IND Sponsor 
when needed for periodic safety assessments, revi ew of IND annual reports, review of IND safety 
reports, and preparation of final study reports. 
9.4.2 Serious Adverse Events 
All SAEs (regardless of relationship and whether or not they are also UPs) must be reported on the 
Safety Expedited Report Form (SERF) and sent to the Sponsor Clinical Safety Office (CSO) by [CONTACT_3719] e-mail attachment. Deaths and immediately life threatening SAEs must be reported to the CSO within [ADDRESS_909963] INFORMATION:  
 
Clinical Safety Office [ADDRESS_909964] Frederick, MD [ZIP_CODE] 
 
Phone [PHONE_070] Fax [PHONE_016] E-mail: [EMAIL_007]  
9.4.[ADDRESS_909965] be reported to the CSO and sent by [CONTACT_418056] e-mail attachment no later than 7 calendar days of site awareness of the event. UPs that are not 
AEs are not reported to the Sponsor CSO. 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 47 
 
Report all UPs that are also adverse events to the CSO on the NIH Problem Report Form. 
9.4.4 Pregnancy  
Pregnancy itself is not an AE. However, complica tions of pregnancies are AEs and may be SAEs.  
Pertinent obstetrical information for all pregnanci es will be reported to the CSO via fax or email 
within 3 business days from site awareness of the pregnancy.   
 
Pregnancy outcome data (e.g., delivery outco me, spontaneous or elec tive termination of the 
pregnancy) will be reported to the CSO within 3 busine ss days of the site’s awareness on a 
protocol-specified form. 
 
In the event of a pregnancy, the following steps will be taken:  
x Discontinuation of the study agent 
x Withdraw from the study but continue in follow up for safety 
x Report to IRB, sponsor and SMC 
x Advise research subject to notify the obstetrician of study agent exposure 
9.5 R EPORTING PROCEDURES TO THE NIAID  IRB   
9.5.1 Expedited Reporting to the NIAID IRB  
Serious and non-serious Unanticipated Problems,  deaths, serious deviations, and serious or 
continuing non-compliance will be reported with in 7 calendar days of investigator awareness. 
Serious Adverse Events that are possibly, probably, or definitely related to the research will be reported to the NIAID IRB within 7 calendar days of investigator’s a wareness, regardless of 
expectedness. 
9.5.[ADDRESS_909966] of the protocol will not be reported to the IRB unless they 
occur at a rate greater than anticipated by [CONTACT_3476]. Expected adverse events will not be 
reported to the IRB unless they occur at a rate gr eater than that known to oc cur in patients with 
CVID and/or CVID enteropathy. If the rate of th ese events exceeds the rate expected by [CONTACT_123894], the events will be classified and reported as though they are unanticipated problems. Deaths 
related to the natural history of CVID and/or CVID  enteropathy will be reported at the time of 
continuing review.  
9.5.3 Annual Reporting to the NIAID IRB  
The following items will be reported to the NI AID IRB in summary at the time of Continuing 
Review: 
x Serious and non-serious unanticipated problems  
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909967] not resolved by [CONTACT_1008]-up period are followed until final outcome is known. If it is not possible to obtain a final ou tcome for an SAE (e.g., the subject is lost to  follow-
up), the reason a final outcome could not be obtained will be recorded by [CONTACT_673403].   SAEs that occur after the study follow-up period of six months that are reported to and are assessed by [CONTACT_110515], probably, or definitely related must be reported to the CSO, as described above. 
9.7 S
PONSOR ’S REPORTING RESPONSIBILITIES  
Serious and unexpected suspected adverse reacti ons (S[LOCATION_003]Rs) as defined in 21 Code of Federal 
Regulations (CFR) 312.32 and determined by [CONTACT_673404] D Sponsor will be reported to FDA and all 
participating Investigators as IND Safety Reports.  
 
The IND Sponsor will also submit an IND Annual  Report of the progress of the investigation to 
the FDA as defined in 21 CFR 312.33.  
9.8 H ALTING CRITERIA FOR THE PROTOCOL  
Halting the study requires immediate discontinuation of study agent administered for all subjects 
and suspension of enrollment until a decision is made whether or not to continue study agent 
administration.   
The halting criteria (as determined by [CONTACT_978]) for an individual site include:  
x Two or more subjects experience the same or similar SAEs that are unexpected and are 
possibly, probably, or definitely related to the study agent  
OR 
x Any safety issue that the site investigators determine should halt the study  
 
The halting criteria (as determined by [CONTACT_9154] [INVESTIGATOR_673358]) for this study include: 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 49 
 
x Two or more of the same or similar AE in differ ent subjects that are grade 3 or above and are 
unexpected and possibly, probably, or definitely related to the study agent  
OR 
x Any safety issue that the study PI [INVESTIGATOR_673359], the IND Sponsor, or the FDA may halt th e study at any time following review of any 
safety concerns .  In addition, the SMC may recommend a study halt.  
9.8.1 Reporting of Study Halting 
If a halting requirement is met, a description of the ev ent(s) or safety issue must be reported by [CONTACT_1600] [INVESTIGATOR_673360]. The PI [INVESTIGATOR_673361] a halting rule has been met. 
9.8.[ADDRESS_909968] OR GROUP  
The decision to suspend administration of the study agent(s) for a single subject or for all subjects 
in a specific group requires discontinuation of stud y agent administrated for the study subject(s) 
or group until a decision is made whether or not to continue study agent administration.   
The pausing criteria for a single subject or for the sub jects in a specific group in this study include:  
x A subject  experiences an SAE or Grade 3 or greater AE that is unexpected (as determined by 
[CONTACT_9533]) and is possibly, probably, or definitely related to the study agent;  
OR 
x Any safety issue that the PI [INVESTIGATOR_322870] a 
single subject or to all subjects in a specific group.            O R  
x If any subject develops any concomitan t illness that requires administration of 
immunosuppressive agents that will impact this study. 
 
The IND Sponsor, in collaboration with the PI, may al so pause for an individual subject or entire 
group if a safety concern is identified during routine aggregate data analysis. 
9.9.[ADDRESS_909969] or Group 
If a pausing requirement is met, a description of th e adverse event(s) or safety issue must be 
reported by [CONTACT_673405], PI, 
the IRB and the SMC.  The PI [INVESTIGATOR_673362] a pausing rule has been met.   
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909970]/group. The IND Sponsor will notify the Site 
Investigators of this decision. The Site Investigat ors will notify their local IRB of the decision to 
resume administration of the study agent prior to resumption. 
If a subject has been paused for less than or equal to 5 half lives ( t1⁄2 ~ 21 days, thus 5 half lives 
are 105 days) of ustekinumab and it is deemed sa fe to resume administration of study drug, the 
subject will not require re-induction (270 mg indu ction dose) and will complete remaining study 
visits, testing and treatments. 
If a subject has been paused for  greater than 5 half lives ( t1⁄2 ~ 21 days, thus 5 half lives are 105 
days) of ustekinumab and it is deemed to be safe  to resume administration of study drug, the subject 
will require re-induction (270 mg induction dose) a nd will repeat all study visits, testing and 
treatments from Day 0 through Week 48. Pre-treat ment eligibility studies (including malabsorption 
studies and endoscopy with biopsies) do not need to be repeated.  The subject will not need to be 
re-consented, unless there has been an amendment to the study. 
9.[ADDRESS_909971] will be withdrawn for any of the following:  
x An individual subject’s decision.  Subjects will be allowed to withdraw at any time, even 
after receiving the study agents, although withdrawal at these stages would be highly discouraged.  Withdrawn subjects who received the study agent will be asked to return 
approximately [ADDRESS_909972], blood culture, and/or chest CT.  Investig ator should attempt to determine the reason for 
the subject’s decision to withdraw.  
x Any clinical AE, laboratory abnormality or other medical condition or situation such that 
continued participation in the study would not be in the best interest of the subject.  Subjects 
will be followed for the duration of the study for indicated safety assessments. 
x Non-compliance with study procedures to the extent that it is potentially harmful to the 
subject or to the integrity of the study data. 
x A change in the subject’s baseline condition after enrollment so that the subject no longer 
meets any of the following inclusion/exclusion crite ria. In particular, if any subject develops 
any concomitant illness that requires admini stration of immunosuppressive agents study 
agent will be suspended. 
x If an individual subject has shown no clinical response with no improvement in 
malabsorption testing parameters at Week 24, no further study agent will be administered 
after the Week [ADDRESS_909973] who is removed or drops out of th e study before the Week 24 study point may be 
replaced. 
9.12 S AFETY OVERSIGHT  
9.12.1 Safety Review and Communications Plan (SRCP) 
A Safety Review and Communication Plan (SRC P) has been developed for the protocol. The 
SRCP is an internal communications document be tween the Principal Investigator [INVESTIGATOR_673363] (CSO) , which delineates the safety oversight responsibilities of the 
PI, the CSO, and other stakeholders. The SRCP  also includes the overall plan for conducting 
periodic safety surveillance assessments.  
9.12.2 Sponsor Medical Monitor (SMM) 
A Medical Monitor, representing the IND Sponsor (OCRPRO), has been appointed for oversight 
of safety in this clinical study. The Sponsor Medical Monitor will be responsible for performing safety assessments as outlined in a Safety  Review and Communications Plan (SRCP).  
9.12.3 Safety Monitoring Committee (SMC) 
 
An independent SMC, including [ADDRESS_909974] data on safety, 
enrollment and drop-out data as well as all study re sults that are available.  The SMC will review 
all SAEs and will also review safety data as needed in response to AEs considered medically significant by [CONTACT_978].   After each SMC review, a recommenda tion as to whether the study is to 
continue, be modified, or be ter minated will be provided in a summ ary report.  All serious adverse 
events, all unanticipated problems and all IND Safety  Reports will be reported by [CONTACT_978] [INVESTIGATOR_673364] e IRB or IND Sponsor. The SMC will be notified 
immediately if pausing or halting rules are met and the SMC will provide a recommendation for 
continuation, modification, or termi nation of the study.  The PI [INVESTIGATOR_673365].  All privacy and confidentiality of all 
participants will be maintained as per NIH guidelines and policy. 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 52 
10.0 DATA MANAGEMENT AND PROTOCOL MONITORING PLAN 
As per International Conference on Harmonization (ICH) GCP 5.18 and  FDA 21 CFR 312.50, 
clinical protocols are required to  be adequately monitored by [CONTACT_4530]. This study 
monitoring will be conducted according to the “NIAID Intramural Clinical Monitoring 
Guidelines.” Monitors under contract to the NIAID Office of Clinical Research Policy and 
Regulatory Operations (OCRPRO) will visit the cl inical research site to monitor aspects of the 
study in accordance with the appropriate regulati ons and the approved protocol. The objectives of 
a monitoring visit will be:  
x To verify the existence of signed informed  consent documents a nd documentation of the 
informed consent process for each monitored subject;  
x To verify the prompt and accurate recording of  all monitored data points and prompt reporting 
of all SAEs;  
x To compare CRI MSON data abstracts with individual s ubjects’ records and source documents 
(subjects’ charts, laboratory analyses and test results, physicians’ progress notes, nurses’ notes, and any other relevant original subject information); and  
x To help ensure investigators are in compliance with the protocol. The monitors also will inspect 
the clinical site regulatory files to ensure that regulatory requirements OHRP, FDA, and applicable guidelines (ICH-GCP) are being fol lowed. During the monitoring visits, the 
investigator (and/or designee) and other study pers onnel will be available to discuss the study 
progress and monitoring visit. 
The investigator (and/or designee) will make study  documents (e.g., consent forms and CRIMSON 
data abstracts) and pertinent hospi[INVESTIGATOR_673366],  the FDA, the site monitors, and the NIAID staff for confirmation of the study data.  
A specific protocol monitoring plan will be di scussed with the PI [INVESTIGATOR_894]. The plan will outline the frequency of m onitoring visits based on such factors as study 
enrollment, data collection stat us, and regulatory obligations. 
10.[ADDRESS_909975] KEEPI[INVESTIGATOR_1645]  
10.1.1 Data Management Responsibilities 
The Investigator is responsible for assuring th at the data collected are complete, accurate, and 
recorded in a timely manner. Source documentati on (the point of initial recording of information) 
should support the data collected in the electronic data system and must be signed and dated by 
[CONTACT_1024]/or reviewing the data. All data should be reviewed by [CONTACT_673406]. 
The data collected under prior vers ion of protocol for Cohort 1 subjects (n=3) will be analyzed 
separately from data collected under revised protoc ol (n=10). This later analysis will include prior 
treated subjects if they meet eligibility criteria. 
10.1.2 Data Capture Methods 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 53 
Study data will be collected at the study site  and maintained in CRIMSON. This system will be 
completed on an ongoing basis during the study. Data entry into CRIMSON will be performed by 
[CONTACT_4539]. Corrections will be tr acked electronically (password protected or through 
an audit trail) with time, date, individual making the correction, and what was changed. 
10.1.[ADDRESS_909976]’s medical records, laboratory reports, 
ECG tracings, subject’s diaries, biopsy reports, progress notes, pharmacy records, and any othe r 
similar reports or records of procedures performed during the subject’s participation in the study.  
10.1.4 Source Documents and Access to Source Data/Documents 
Source documents include all recordings of observati ons or notations of clinical activities, and all 
reports and records necessary for the evaluation and re construction of the clinical trial. Data from 
CRIMSON will be collected directly from subjec ts during study visits and telephone calls, or will 
be abstracted from the subjects’ medical records. The subject’s medical record must record his/her 
participation in the clinical trial and study treatm ent (with doses and frequency) or other medical 
interventions or treatments administered, as well  as any AEs experienced during the trial.  
10.1.[ADDRESS_909977] Retention 
The investigator is responsible for retaining all essential documents listed in the ICH-GCP 
Guideline. All essential documentation for all study subjects will be maintained by [CONTACT_83196] a secure storage facility for  a minimum of 3 years per NIAID policies. The FDA 
requires study records to be retained for up to 2 years after marketing approval or disapproval (21 
CFR 312.62), or until at least [ADDRESS_909978]. All stored re cords will be kept confidential to  the extent required by [CONTACT_1032], 
state, and local law.  
Should the investigator wish to assign the stud y records to another party and/or move them to 
another location, the investigator will provide  written notification of such intent to 
OCRPRO/NIAID with the name [CONTACT_673410] w ill accept responsibility for the transferred 
records and/or their new location. NIAID will be notified in writing. Destruction or relocation of 
research records will not proceed without written permission from OCRPRO/NIAID. 
10.2 D
ATA SHARING  
 
Human data generated in this study for future research will be shared as follows: 
x Identified data in the Biomedical Translational Research Information System of the NIH 
(BTRIS). 
x De-identified or identified data with approv ed outside collaborators under appropriate 
agreements. 
 
Data will be shared through: 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 54 
x BTRIS. 
x Approved outside collaborators under appropriate individual agreements. 
x Publication and/or public presentations. 
  
Data will be shared before publication and/or at  the time of publication or shortly thereafter. 
11.[ADDRESS_909979]. Both th e specimens and the file will be stored in locked 
storage units within a locked room for the purpose of maintaining confidentiality. These specimens 
may be used in collaborative research, but the spec imens will not be able to be linked with specific 
subjects. The future research use of these stored specimens will be conducted in accordance with 
policy set by [CONTACT_673407]. Any transport of blood specimen s to the study sponsor will be provided by [CONTACT_673408] (IATA) and 
the Department of Transportation for shipment  of biologically hazardous materials.  Any 
unanticipated loss or dest ruction of samples or data will be reported to the IRB.  Upon termination 
of this protocol all patient samples and data will be destroyed or with IRB approval transferred to 
another existing protocol or repository. 
12.0 REMUNERATION 
Subjects will not be paid for their participation in  this protocol. Travel expenses may be paid on a 
case-by-case basis.  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 55 
REFERENCES 
1) Aukrust, P. et al. 1996. Persistent Activati on of the Tumor Necrosis Factor System in a 
Subgroup of Patients With Common Variable Immunodeficiency--Possible Immunologic and Clinical Consequences. Blood, v. 87, n. p. 674-681. 
2) Brugnoni, D et al. 1996. Cd4+ Cells From Patients With Common Variable 
Immunodeficiency Have a Reduced Ability of Cd40 Ligand Membrane Expression After in 
vitro Stimulation. Ped. Allergy Immunol, v. 7, n. p. 176-179. 
3) Bryant, A et al. 1990. Classification of Patients With Common Variable Immunodeficiency 
By B Cell Secretion of IgM and IgG in Response to IgM and Interleukin-2. Clinical Immunology and Immunopathology, v. 56, n. p. 239-248. 
4) Cambronero, R. et al. 2000. Up-Regulation of Il-12 in Monocytes: a Fundamental Defect in 
Common Variable Immunodeficiency. J. Immunol, v. 164, n. p. 488-494. 
5) Cappell, MS. 1996. Gastrointestinal Endoscopy in  High-Risk Patients. Digestive Diseases, 
v. 14, n. p. 228-244. 
6) Castellano, G et al. 1992. Malignant Lymphoma of the Jejunum With Common Variable 
Hypogammaglobulinemia and Diffuse Nodular Hyperplasia of the Small Intestine. Journal of Clinical Gastroenterology, v. 15, n. p. 281. 
7) Catassi, C et al. 1988. Unresponsive Enteropat hy Associated With Circulating Enterocyte 
Autoantibodies in a Boy With Common Variable Hypogammaglobulinemia and Type I Diabetes. Journal of Pediatric Gastroenterology and Nutrition, v. 7, n. p. 608-613. 
8) Chapel H, Geha R, Rosen F. 2003. IUIS PID (Primary Immunodeficiencies) Classification 
committee.  Primary immunodeficiency diseases: an update.  Clinical & Experimental 
Immunology. v. 132, n.p. 9-15.  
9) Committee, IUISS 1999. Primary Immunodeficien cy Diseases. Clinical & Experimental 
Immunology, v. 118, n. Suppl. 1, p. 1-28. 
10) Craig, RM, Atkinson, AJ. 1988. D-Xylose Testing: a Review. Gastroenterology, v. 95, n. p. 
223-231. 
11) Cunningham-Rundles, C, Bodian, C. 1999. Common Variable Immunodeficiency: Clinical 
and Immunological Features of 248 Patients. Clinical Immunology, v. 92, n. p. 34-48. 
12) Cunningham-Rundles, C, Radigan, L. 2005. Defici ent Il-12 and Dendritic Cell Function in 
Common Variable Immune Deficiency. Clinical Immunology v. 115, n. p. 147-153. 
13) Damore, LJ et al. 1996. Colonoscopic Perforat ions: Etiology, Diagnosis, and Management. 
Diseases of the Colon and Rectum, v. 39, n. p. 1308-1314. 
14) Duraisingham, SS et al. 2015. Immune Deficiency: Changing Spectrum of Pathogens. Clin 
Exp Immunol, v. 181(2), n. p. 267-274. 
15) Eckardt, VF, Gaedertz, C, Eidner, C. 1997. Colonic Perforation With Endoscopic Biopsy. 
Gastrointestinal Endoscopy, v. 46, n. p. 560-562. 
16) Farrant, J et al. 1994. Study of B and T Cell Phenotypes in Blood From Patients With 
Common Variable Immunodeficiency (CVID). Immunodeficiency, v. 5, n. p. 159-169. 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 56 
17) Farrington, M et al. 1994. Cd40 Ligand Expression is Defective in a Subset of Patients 
With Common Variable Immunodeficiency. Proceedings of the National Academy of 
Sciences of the [LOCATION_002] of America, v. 91, n. p. 1099-1103. 
18) Fischer, MB et al. 1994. A Defect in the Ea rly Phase of T-Cell Receptor-Mediated T-Cell 
Activation in Patients With Common Variable Immunodeficiency. Blood, v. 84, n. p. 4234-4241. 
19) Fischer, MB et al. 1993. Activation of Cvid Pa tients' T Cells With Conventional Antigens 
and Superantigens. Immunodeficiency, v. 4, n. p. 15-16. 
20) Florescu, DF et al. 2011. Is there a role for oral human immunoglobulin in the treatment for 
norovirus enteritis in immunocompromised patients? Ped Transplant. V. 15, n.p. 718-721. 
21) Foliente, RL et al. 1996. Endoscopic Cecal Perforation: Mechanisms of Injury. American 
Journal of Gastroenterology, v. 91, n. p. 705-708. 
22) Froehlich, F et al. 1999. Appropriateness of Gastrointestinal Endoscopy: Risk of 
Complications. Endoscopy, v. 31, n. p. 684-686. 
23) Geha, RS. 1988. IgG antibody response to polysaccharides in children with recurrent 
infections. Monogr Allergy, v. 23, n.p. 97-102. 
24) Green, KY. 2014. Norovirus infection in imm unocompromised hosts. Clin. Microbiol. And 
Infect. V. 20., n.p. 717-72 
25) Grimbacher, B et al. 2003. Homozygous Loss of Icos is Associated With Adult-Onset 
Common Variable Immunodeficiency. Nature Immunology, v. 4, n. p. 261-268. 
26) Gupta, S, Damle, NK. 1983. Autologous Mixed Lymphocyte Reaction in Man  Iv. 
Decreased Autologous Mixed Lymphocyte Culture Response in Patients With Comon 
Variable Immunodeficiency. Journal of Clinical Immunology, v. 3, n. p. 78-83. 
27) Hart, R, Classen, M. 1990. Complications of Diagnostic Gastrointestinal Endoscopy. 
Endoscopy, v. 22, n. p. 229-233. 
28) Herbst, EW et al. 1994. Intestinal B Cell Defects in Common Variable Immunodeficiency. 
Clinical & Experimental Immunology, v. 95, n. p. 215-221. 
29) Irvine, EJ, Hunt, RH. 1997. Endoscopy--Lower Intestinal Tract. In: Allan, RN, Rhodes, 
JM, Hanauer, SB, Keighley, MRB, Alexander-Wi lliams, J, Fazio, VW (eds.), Inflammatory 
Bowel Diseases. [LOCATION_001]: Churchill Livingstone. 
30) Jacquot, S et al. 2001. B Cell Co-Receptors Regulating T Cell-Dependent Antibody 
Production in Common Variable Immunodeficiency: Cd27 Pathway Defects Identify 
Subsets of Severely Immuno-Compromised Patients. International Immunology, v. 13, n. p. 
871-876. 
31) Jaffe, JS, Strober, W, Sneller, MC 1993. Functi onal Abnormalities of Cd8+ T Cells Define 
a Unique Subset of Patients With Common Variable Immunodeficiency. Blood, v. 82, n. p. 192-201. 
32) Kolho, KL et al. 2012. Enteric viral pathogens in children with inflammatory bowel 
disease. J. Med Virol. V. 84, n.p. 345-347. 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 57 
33) Kondratenko I, Amlot PL, Webster AD, Farrant J.  1997. Lack of specific antibody 
response in common variable immunodeficiency (CVID) associated with failure in 
production of antigen-specific memory T cells. MRC Immunodeficiency Group. Clinical & Experimental Immunology. Apr;108(1):9-13. 
34) Kontoyiannis, D et al. 1999. Impaired on/Off Regulation of Tnf Biosynthesis in Mice 
Lacking Tnf Au-Rich Elements: Implications for Joint and Gut-Associated Immunopathologies. Immunity, v. 10, n. p. 387-398. 
35) Lederman, H, Winkelstein, J. 1985. X-Linked Agammaglobulinemia: an Analysis of 96 
Patients. Medicine, v. 64, n. p. 145-156. 
36) Lichtenstein, G. 2016. CCFA Advances in Inflammatory Bowel Diseases 2015: Highlights 
in Ulcerative and Crohn’s disease. Gastroen terology and Hepatology. 12(2): Supplement 1. 
P. 7-19. 
37) Macrae, FA, Tan, KG, Williams, CB. 1983. To wards Safer Colonoscopy: a Report on the 
Complications of 5000 Diagnostic Or Therapeutic Colonoscopi[INVESTIGATOR_014]. Gut, v. 24, n. p. 376-383. 
38) Mannon, PJ et al. 2004. Anti-Interleukin-12 antibody for active Crohn's disease. New 
England Journal of Medicine, v. 351, n.p. 2069-79.  
39) Mannon, PJ. et al. 2006. Excess IL-12 but not IL-23 accompanies the inflammatory bowel 
disease associated with common variable immunodeficiency. Gastroenterology, v. 131, n. 
p. 748-56.  
40) Martinot, M. et al. 2014. Immunoglobulin defi ciency in patients with Streptococcus 
pneumoniae or Haemophilus influenza infecti ons. Int J Infect Dis. V.19, n.p. 79-84. 
41) Masclee, GM et al. 2013. Enteropathogenic viruses: triggers for exacerbation in IBD? A 
prospective cohort study using real time quantitative polymerase chain reaction. Inflamm Bowel Dis. V. 19, n/p/ 124-131. 
42) Moriuchi, H et al. 1990. Pernicious Anemia in a Patient With Hypogammaglobulinemia. 
Acta Paediatrica Japonica, v. 32, n. p. 311-314. 
43) Nelson, AM et al. 2013. Murine norovirus infection does not cause major disruptions in the 
murine intestinal microbiota. Microbiome. V.1, n.p. 1-7.  
44) North, M, Webster, ADB, Farrant, J. 1991. Defects in Proliiferative Responses of T Cells 
From Patients With Common Variable Immunodeficiency on Direct Activatio of Protien Kinase C. Clinical & Experimental Immunology, v. 85, n. p. 198-201. 
45) North, M, Webster, AD, Farrant, J. 1998. Primary Defect in Cd8+ Lymphocytes in the 
Antibody Deficiency Disease (Common Variable Immunodeficiency): Abnormalities in 
Intracellular Production of Interferon-Gamma (Inf-Gamma) in Cd28+ ('Cytotoxic') and Cd28- ('Suppressor') Cd8+ Subsets. Clinical & Experimental Immunology, v. 111, n. p. 70-75. 
46) O’Connor, JPA et al. 2009. Use of Infli ximab as rescue therapy in acute severe Ulcerative 
colitis with recent norovirus infection. J Crohn ’s Colitis. V.3, n.p. 204-206. 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 58 
47) Quiniti, I. et al. 2011. Effectiveness of Immunoglobulin replacement therapy on clinical 
outcome in patients with primary antibody deficiencies: results from a multicenter 
prospective cohort study. J Clin. Immunol. V. 31, n.p. 315-322. 
48) Raijman, I, Sellin, J, Glombicki, A. 1992. Ga strointestinal Bleeding After Cold Biopsy. 
Gastrointestinal Endoscopy v. 38, n. p. 636. 
49) Ryan, J. 1996. Premalignant Lesions of the Small Intestine. Seminars in Gastrointestinal 
Disease, v. 7, n. p. 88-93. 
50) Salzer, U et al. 2005. Mutations in TNFRSF 13B Encoding TACI Are Associated With 
Common Variable Immunodeficiency in Humans. Nature Genetics, v. 37(8) p. 820-8. 
51) Sandborn, WJ et al. 2008. A randomized tria l of Ustekinumab, a human interleukin-12/23 
monoclonal antibody, in patients with moderate-to-severe Crohn's disease. 
Gastroenterology, v. 135, n. p. 1130-41. 
52) Sandborn, WJ et al. 2012. Ustekinumab inducti on and maintenance therapy in refractory 
Crohn's disease. New England Journal of Medicine, v. 367, n. p. 1519-28. 
53) Serrano, D et al. 2000. Characterization of the T Cell Receptor Repertoire in Patients With 
Common Variable Immunodeficiency: Oligoclona l Expansion of Cd8(+) T Cells. Clinical 
Immunology, v. 97, n. p. 248-258. 
54) Shiffman, ML, Farrel, MT, Yee, YS. 1994. Risk of Bleeding After Endoscopic Biopsy Or 
Polypectomy in Patients Taking Aspi[INVESTIGATOR_673367]. Gastrointestinal Endoscopy, v. 40, n. p. 458-462. 
55) Sneller, M et al. 1993. NIH Conference: New Insights Into Common Variable 
Immunodeficiency. Annals of Internal Medicine, v. 118, n. p. 720-730. 
56) Stagg, AJ et al. 1994. Failure in Antigen Responses By T Cells From Patients With 
Common Variable Immunodeficiency (CVID). Clinical & Experimental Immunology, v. 96, n. p. 48-. 
57) Sugita, K et al. 1993.  An infant with both neutropenia and idiopathic thrombocytopenia 
with IgG2/IgA deficiency.  In J Hematol. V. 57, n. p. 27-30. 
58) Teahon, K et al. 1994. Studies on the Enteropathy Associated With Primary 
Hypogammaglobulinemia. Gut, v. 35, n. p. 1244-1249. 
59) Terheggen, G et al.  2008. Safety, Feasability,  and Tolerability of Ileocolonoscopy in 
Inflammatory Bowel Disease. Endoscopy, v. 40(8), p. 656-63. 
60) Thon, V et al. 1997. Antigen Presentation By [CONTACT_673409] 
(CVID) B Cells and Monocyte is Unimpair ed. Clinical & Experimental Immunology, v. 
108, n. p. 1-. 
61) Trinchieri G. 1998. Proinflammatory and im munoregulatory functions of interleukin-12.  
Int Rev Immunol. v. 16(3-4), p. 365-96. 
62) Twomey, J et al. 1970. The Gastric Disorders in Immunoglobulin Deficient Patients. 
Annals of Internal Medicine, v. 72, n. p. 499. 
63) Umetsu, DT., 1985. Recurrent sinopulmonary inf ection and impaired antibody response to 
bacterial capsular polysaccharide antigen in children with selective IgG subclass 
deficiency. N Engl. J. Med. V 313, n.p. 1247-1251. 
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 59 
64) Van den Brande, P et al. 1988. Intestinal Nodular Lymphoid Hyperplasia in Patients With 
Common Variable Immunodeficiency: Local Accumulation of B and Cd8(+) 
Lymphocytes.. Journal of Clinical Immunology, v. 8, n. p. 296-306. 
65) Viallard, JF et al. 2005. Altered Dendritic Cell Distribution in Patients With Common 
Variable Immunodeficiency. Arthritis Research & Therapy, v. 7, n. p. R1052-R1055. 
66) Wagner, D et al. 1988. Dysgonic Fermenter 3- Associated Gastrointestinal Disease in a 
Patient With Common Variable Hypogammaglobulinemia. American Journal of Medicine, v. 84, n. p. 315-318. 
67) Waldman, TA et al. 1974. Role of Suppressor Cells in Pathogenesis of Common Variable 
Hypogammaglobulinemia. Lancet, v. 2, n. p. 609-616. 
68) Warnatz, K et al. 2002. Severe Deficiency of Switched Memory B Cells (Cd27+Igm-Igd-) 
in Subgroups of Patients With Common Va riable Immunodeficiency: a New Approach to 
Classify a Heterogeneous Disease. Blood, v. 99, n. p. 1544-1551. 
69) Washington, K et al. 1996. Gastrointestinal Pathology in Patients With Common Variable 
Immunodeficiency and X-Linked Agammagl obulinemia. American Journal of Surgical 
Pathology, v. 20, n. p. 1240-1252. 
70) Wright, JJ et al. 1990. Characterization of Common Variable Immunodeficiency: 
Identification of a Subset of Patients With Distinctive Immunophenotypic and Clinical Features. Blood, v. 76, n. p. 2046-2051. 
71) Wright, P, Sears, D. 1987. Hypogammaglobul ilnemia and Pernicious Anemia. Southern 
Medical Journal, v. 80, n. p. 243-246. 
72) Yao, MD et al. 2009. Multiple Endoscopic Biopsie s in Research Subjects: Safety Results 
from an NIH Series. v. 69, n.p. 911-3. 
73) Zullo, A et al. 1999. Gastric Pathology in Patients With Common Variable 
Immunodeficiency. Gut, v. 45, n. p. 77-81. 
  
Ustekinumab for CVID-GI 
Protocol Version [ADDRESS_909980]: Twenty-five g D-xylose PO will be given after an overnight fast.  
At one hour a blood sample will be drawn; the lowe r limit of is 20 mg/dl.  Adjustment for the 
interpretation of results will be made in the presence of moderately impaired renal function 
(creatinine clearance >30 mL/min) ( Craig  and Atkinson, 1988 ).  
2.  Quantitative Stool Fat: Subjects will be placed on a defined fat diet (e.g. 60-100 g/day) during 
the [ADDRESS_909981] ool will be collected 
into pre-weighed containers prior to homogenizat ion and fat content determination.  Excretion of 
>6% of the estimated daily fat intake will be considered abnormal. 
3. Alpha-1 Antitrypsin (A1AT) Fecal Clearance: S ubjects will collect st ool output for a defined 
24 hour period for measurement of stool volume and A1AT concentration.  A simultaneous blood 
sample for serum A1AT will be drawn in order to calculate the A1AT fecal clearance.  Values >50 
mg/24hr will be considered abnormal.  
4.  Fecal Calprotectin:  Calprotectin is a protein that can be excr eted intact in the stool in cases of 
malabsorption or diseases causing inflammation of the bow el. It is a stool (fecal) test that therefore, 
is used to detect inflammation or malbsorption in the intestines. The calprotectin test however, is 
not diagnostic but can follow indirectly a pati ents degree of malabsorption and/or intestinal 
inflammation.    
  
Ustekinumab for CVID-GI 
Protocol Version 13 
April 17, 2018 61 
 
APPENDIX B - STELARA® FORMULARY DOSSIER (DATA SHEET) 
APPENDIX C - STELARA® PRESCRIBING INFORMATION 
APPENDIX D - STELARA® PATIENT INFORMATION SHEET 
APPENDIX E - SCHEDULE OF EVENTS 
APPENDIX F - PREGNANCY AVOIDANCE PATIENT HANDOUT 
APPENDIX G - COHORT 1 SINGLE DOSE STUDY ADVERSE EVENTS 